David Rimm, MD, PhD

• Adebowale Adeniran
• Ala F Nassar
• Alessandro Santin
• Allen Bale
• Andrea Silber
• Anees Chagpar
• Angelique W. Levi
• Anna Wurtz
• Anne Chiang
• Anup Sharma
• Bal Krishna Chaube
• Barbara Burtness
• Brenda Cartmel
• Catherine Sullivan
• Christos Hatzis
• Craig B. Wilen
• Curtis Jamison Perry
• Daniel Boffa
• Daniel P. Petrylak
• Daniel Zelterman
• David A. Braun
• David F. Stern
• David J Leffell
• David Schoenfeld
• Diane Kowalski
• Don Nguyen
• Donald Lannin
• Edward Kaftan
• Eric Winer
• Erin Hofstatter
• Fangyong Li
• Francisco Exposito
• Frank Detterbeck
• Gary Désir
• Guoping Cai
• Harriet Kluger
• Heather Lazowski
• Herta Chao
• Hongyu Zhao
• Jacky Yeung
• James Dziura
• Jeffrey Ishizuka
• Jeffrey Townsend
• Jennifer McNiff
• Jesse Rinehart
• John Kunstman
• John Sinard
• John Wysolmerski
• Jon Morrow
• Jose Costa
• Joseph Madri
• Joseph Schlessinger
• Joshua VanHouten
• Justin Persico
• Katerina Politi
• Kenneth Williams
• Kerin Adelson
• Kim Blenman
• Kurt Schalper
• Lajos Pusztai
• Lieping Chen
• Lingeng Lu
• Liva Andrejeva-Wright
• Lori Charette
• Lucia Jilaveanu
• Lynn Tanoue
• Malini Harigopal
• Marcus Bosenberg
• Mario Sznol
• Mariya Rozenblit
• Marta Baro
• Masoud Azodi
• Matthew Vesely
• Maura Harrigan
• Melinda Irwin
• Michael DiGiovanna
• Michael Hurwitz
• Michal Marczyk
• Murat Gunel
• Navid Hafez
• Neal Fischbach
• Patricia LoRusso
• Pei Hui
• Peter Gershkovich
• Peter M. Glazer
• Peter Whang
• Qin Yan
• Robert Camp
• Robert Homer
• Rolando Garcia Milian
• Roy S. Herbst
• Ruth Halaban
• Ruth R Montgomery
• Sabine Lang
• Sameet Mehta
• Sanjay Aneja
• Sarah Goldberg
• Scott Gettinger
• Silvia Vilarinho
• Stephan Ariyan
• Thazin Nwe Aung
• Thomas Hayman
• Tian-Min Chen
• Tristen Park
• William Damsky
• Yajaira Suarez
• Yalai Bai
• Yao Li
• Yuval Kluger
• Zuoheng Anita Wang

Breast Neoplasms; Immunohistochemistry; Medical Oncology; Melanoma; Pathology; Biomarkers, Pharmacological

• Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic TestFernandez A, Gaule P, Rimm D. Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test. Modern Pathology 2023, 36: 100159. PMID: 36925070, PMCID: PMC10502188, DOI: 10.1016/j.modpat.2023.100159.
• Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and BeyondLozar T, Laklouk I, Golfinos A, Gavrielatou N, Xu J, Flynn C, Keske A, Yu M, Bruce J, Wang W, Kuhar C, Bailey H, Harari P, Dinh H, Rimm D, Hu R, Lambert P, Fitzpatrick M. Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond. Cancers 2023, 15: 4905. PMID: 37835599, PMCID: PMC10571921, DOI: 10.3390/cancers15194905.
• Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapyMartinez-Morilla S, Moutafi M, Fernandez A, Jessel S, Divakar P, Wong P, Garcia-Milian R, Schalper K, Kluger H, Rimm D. Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy. OncoImmunology 2023, 12: 2260618. PMID: 37781235, PMCID: PMC10540659, DOI: 10.1080/2162402x.2023.2260618.
• Automated scoring of tumour infiltrating lymphocytes informs risk of death from thin melanoma: a nested case-case studyTan S, Aung T, Claeson M, Acs B, Zhou C, Brown S, Lambie D, Baade P, Pandeya N, Soyer H, Smithers B, Whiteman D, Rimm D, Khosrotehrani K. Automated scoring of tumour infiltrating lymphocytes informs risk of death from thin melanoma: a nested case-case study. Journal Of The American Academy Of Dermatology 2023 PMID: 37730017, DOI: 10.1016/j.jaad.2023.09.026.
• Classification of Breast Cancer According to ERBB2 Immunohistochemistry ScoresRobbins C, Fernandez A, Rimm D. Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores. JAMA Oncology 2023, 9: 1298-1299. PMID: 37498606, DOI: 10.1001/jamaoncol.2023.2635.
• Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastasesSchoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.
• Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancerde Miguel F, Gentile C, Feng W, Silva S, Sankar A, Exposito F, Cai W, Melnick M, Robles-Oteiza C, Hinkley M, Tsai J, Hartley A, Wei J, Wurtz A, Li F, Toki M, Rimm D, Homer R, Wilen C, Xiao A, Qi J, Yan Q, Nguyen D, Jänne P, Kadoch C, Politi K. Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell 2023, 41: 1516-1534.e9. PMID: 37541244, DOI: 10.1016/j.ccell.2023.07.005.
• Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastasesChatziioannou E, Roßner J, Aung T, Rimm D, Niessner H, Keim U, Serna-Higuita L, Bonzheim I, Cuellar L, Westphal D, Steininger J, Meier F, Pop O, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine 2023, 93: 104644. PMID: 37295047, PMCID: PMC10363450, DOI: 10.1016/j.ebiom.2023.104644.
• Subsets of interferon signaling and response to immune checkpoint blockade.Lee D, Horowitch B, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of interferon signaling and response to immune checkpoint blockade. Journal Of Clinical Oncology 2023, 41: 9522-9522. DOI: 10.1200/jco.2023.41.16_suppl.9522.
• Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancerBarrera C, Corredor G, Viswanathan V, Ding R, Toro P, Fu P, Buzzy C, Lu C, Velu P, Zens P, Berezowska S, Belete M, Balli D, Chang H, Baxi V, Syrigos K, Rimm D, Velcheti V, Schalper K, Romero E, Madabhushi A. Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer. Npj Precision Oncology 2023, 7: 52. PMID: 37264091, PMCID: PMC10235089, DOI: 10.1038/s41698-023-00403-x.
• Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.Horowitch B, Lee D, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma. Clinical Cancer Research 2023, 29: 2908-2918. PMID: 37233452, PMCID: PMC10524955, DOI: 10.1158/1078-0432.ccr-23-0215.
• Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trialFanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Liu Y, Wang L, Wei W, Pusztai L, Blenman K. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial. Npj Breast Cancer 2023, 9: 38. PMID: 37179362, PMCID: PMC10182981, DOI: 10.1038/s41523-023-00535-0.
• 202 Automated assessment of tumor infiltrating lymphocytes informs mortality in thin melanomaTan S, Aung T, Claeson M, Zhou C, Brown S, Acs B, Lambie D, Baade P, Pandeya N, Soyer H, Smithers B, Whiteman D, Rimm D, Khosrotehrani K. 202 Automated assessment of tumor infiltrating lymphocytes informs mortality in thin melanoma. Journal Of Investigative Dermatology 2023, 143: s34. DOI: 10.1016/j.jid.2023.03.204.
• Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for PathologistsHarms P, Frankel T, Moutafi M, Rao A, Rimm D, Taube J, Thomas D, Chan M, Pantanowitz L. Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists. Modern Pathology 2023, 36: 100197. PMID: 37105494, DOI: 10.1016/j.modpat.2023.100197.
• Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor SpecimensFeng W, Inoue R, Kuwata T, Niikura N, Fujii S, Kumaki N, Honda K, Xu L, Goetz A, Gaule P, Cogswell J, Rimm D, McGee R. Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens. Applied Immunohistochemistry & Molecular Morphology 2023, 31: 339-345. PMID: 37093713, PMCID: PMC10155692, DOI: 10.1097/pai.0000000000001126.
• Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinomaGavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm D. Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma. Cancer Research Communications 2023, 3: 558-563. PMID: 37057033, PMCID: PMC10088911, DOI: 10.1158/2767-9764.crc-22-0299.
• Quantitative, Spatially Defined Expression of Leukocyte Associated Immunoglobulin-like Receptor (LAIR-1) in Non-Small Cell Lung CancerAung T, Gavrielatou N, Vathiotis I, Fernandez A, Shafi S, Yaghoobi V, Burela S, MacNeil T, Ahmed F, Myint H, Flies D, Langermann S, Rimm D. Quantitative, Spatially Defined Expression of Leukocyte Associated Immunoglobulin-like Receptor (LAIR-1) in Non-Small Cell Lung Cancer. Cancer Research Communications 2023, 3: 471-482. PMID: 36960400, PMCID: PMC10029762, DOI: 10.1158/2767-9764.crc-22-0334.
• Spatial characterization and quantification of CD40 expression across cancer typesBates K, Vathiotis I, MacNeil T, Ahmed F, Aung T, Katlinskaya Y, Bhattacharya S, Psyrri A, Yea S, Parkes A, Sadraei N, Roychoudhury S, Rimm D, Gavrielatou N. Spatial characterization and quantification of CD40 expression across cancer types. BMC Cancer 2023, 23: 220. PMID: 36894898, PMCID: PMC9996913, DOI: 10.1186/s12885-023-10650-7.
• Quantitative, Spatially Defined Expression of Leukocyte Associated Immunoglobulin-like Receptor (LAIR-1) in Non-Small Cell Lung CancerAung T, Gavrielatou N, Vathiotis I, Fernandez A, Shafi S, Yaghoobi V, Burela S, MacNeil T, Ahmed F, Myint H, Flies D, Langermann S, Rimm D. Quantitative, Spatially Defined Expression of Leukocyte Associated Immunoglobulin-like Receptor (LAIR-1) in Non-Small Cell Lung Cancer. Cancer Research Communications 2023 DOI: 10.1158/2767-9764.crc-22-0334.
• Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction CancerFernandez A, Robbins C, Gaule P, Agostini-Vulaj D, Anders R, Bellizzi A, Chen W, Chen Z, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan Y, Weidler J, Bates M, Zhang X, Rimm D. Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer. Modern Pathology 2023, 36: 100128. PMID: 36889057, PMCID: PMC10198879, DOI: 10.1016/j.modpat.2023.100128.
• Multi-institutional study of pathologist reading of the PD-L1 combined positive score (CPS) immunohistochemistry assay in gastric or gastroesophageal junction cancerFernandez A, Robbins C, Gaule P, Agostini-Vulaj D, Anders R, Bellizi A, Chen W, Chen Z, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan Y, Weidler J, Bates M, Zhang X, Rimm D. Multi-institutional study of pathologist reading of the PD-L1 combined positive score (CPS) immunohistochemistry assay in gastric or gastroesophageal junction cancer. Modern Pathology 2023, 100128. DOI: 10.1016/j.modpat.2023.100128.
• Multi-institutional Assessment of Pathologist Scoring HER2 ImmunohistochemistryRobbins C, Fernandez A, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba M, Wen H, Sanders M, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir O, Yoon E, Rabe K, Soong T, Reisenbichler E, Rimm D. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. Modern Pathology 2023, 36: 100032. PMID: 36788069, PMCID: PMC10278086, DOI: 10.1016/j.modpat.2022.100032.
• An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor TherapyRimm D. An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy. JAMA Oncology 2023, 9: 60-61. PMID: 36394848, DOI: 10.1001/jamaoncol.2022.4772.
• The Pathologists' Conundrum.Rimm D, Dacic S, Schnitt S. The Pathologists' Conundrum. Archives Of Pathology & Laboratory Medicine 2022, 147: 17-18. PMID: 36577091, DOI: 10.5858/arpa.2022-0226-ed.
• Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockadeVathiotis I, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung T, Shafi S, Wong P, Jessel S, Kluger H, Syrigos K, Warren S, Gerstein M, Rimm D. Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade. Npj Precision Oncology 2022, 6: 92. PMID: 36522538, PMCID: PMC9755314, DOI: 10.1038/s41698-022-00330-3.
• 127 Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance to immunotherapy in melanoma patientsAung T, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis L, Chan N, Kluger H, Rimm D. 127 Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance to immunotherapy in melanoma patients. 2022, a140-a140. DOI: 10.1136/jitc-2022-sitc2022.0127.
• 133 Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinomaGavrielatou N, Warrell J, Aung T, Vathiotis L, Economopoulou P, Burtness B, Psyrri A, Rimm D. 133 Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinoma. 2022, a146-a146. DOI: 10.1136/jitc-2022-sitc2022.0133.
• Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.Hayes D, Herbst R, Myles J, Topalian S, Yohe S, Aronson N, Bellizzi A, Basu Roy U, Bradshaw G, Edwards R, El-Gabry E, Elvin J, Gajewski T, McShane L, Oberley M, Philip R, Rimm D, Rosenbaum J, Rubin E, Schlager L, Sherwood S, Stewart M, Taube J, Thurin M, Vasalos P, Laser J. Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. JCO Precision Oncology 2022, 6: e2200454. PMID: 36446042, PMCID: PMC10530621, DOI: 10.1200/po.22.00454.
• Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importanceSchoenfeld D, Merkin R, Moutafi M, Martinez S, Adeniran A, Kumar D, Jilaveanu L, Hurwitz M, Rimm D, Kluger H. Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance. Frontiers In Oncology 2022, 12: 990367. PMID: 36313654, PMCID: PMC9608089, DOI: 10.3389/fonc.2022.990367.
• Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.Moutafi M, Robbins C, Yaghoobi V, Fernandez A, Martinez-Morilla S, Xirou V, Bai Y, Song Y, Gaule P, Krueger J, Bloom K, Hill S, Liebler D, Fulton R, Rimm D. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Laboratory Investigation 2022, 102: 1101-1108. PMID: 36775350, DOI: 10.1038/s41374-022-00804-9.
• Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer.Shafi S, Aung T, Xirou V, Gavrielatou N, Vathiotis I, Fernandez A, Moutafi M, Yaghoobi V, Herbst R, Liu L, Langermann S, Rimm D. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. Laboratory Investigation 2022, 102: 1143-1149. PMID: 36775354, DOI: 10.1038/s41374-022-00796-6.
• P2.12-01 Intratumoral Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)Porciuncula A, Henick B, Gianino N, Zugazagoitia J, Vathiotis I, Gavrielatou N, Zacharek S, Rimm D, Schalper K. P2.12-01 Intratumoral Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC). Journal Of Thoracic Oncology 2022, 17: s150. DOI: 10.1016/j.jtho.2022.07.249.
• 688P Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC)Moutafi M, Economopoulou P, Kotsantis I, Anastasiou M, Foukas P, Fountzilas G, Rimm D, Psyrri A. 688P Transcriptional profile changes in matched paired tumor samples after PARP inhibitor treatment in head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2022, 33: s857-s858. DOI: 10.1016/j.annonc.2022.07.812.
• Abstract 1094: SMARCA4 -mediated chromatin remodeling regulates osimertinib resistance in EGFR -mutant lung adenocarcinomade Miguel F, Cai W, Melnick M, Robles-Oteiza C, Wurtz A, Toki M, Rimm D, Homer R, Nguyen D, Politi K. Abstract 1094: SMARCA4 -mediated chromatin remodeling regulates osimertinib resistance in EGFR -mutant lung adenocarcinoma. Cancer Research 2022, 82: 1094-1094. DOI: 10.1158/1538-7445.am2022-1094.
• Abstract 1242: PD-L1 and PD-L2 mRNA are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancerFernandez A, Gavrielatou N, McCann L, Shafi S, Moutafi M, Martinez-Morilla S, Vathiotis I, Aung T, Yaghoobi V, Bai Y, Weidler J, Bates M, Rimm D. Abstract 1242: PD-L1 and PD-L2 mRNA are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer. Cancer Research 2022, 82: 1242-1242. DOI: 10.1158/1538-7445.am2022-1242.
• Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)Gregorio M, Nagineni V, Ravi A, Datar I, Mino-Kenudson M, Corredor G, Barrera C, Behlman L, Rimm D, Herbst R, Madabhushi A, Riess J, Velcheti V, Hellmann M, Gainor J, Schalper K. Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC). Cancer Research 2022, 82: 1722-1722. DOI: 10.1158/1538-7445.am2022-1722.
• Abstract 1256: B-cell infiltration is associated with survival outcomes in nivolumab-treated head and neck squamous cell carcinoma (HNSCC): NCT 03652142Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Gkotzamanidou M, Rusakiewics S, Vathiotis I, Aung T, Kotsantis I, Vagia E, Panayiotides I, Rimm D, Coukos G, Foukas P, Psyrri A. Abstract 1256: B-cell infiltration is associated with survival outcomes in nivolumab-treated head and neck squamous cell carcinoma (HNSCC): NCT 03652142. Cancer Research 2022, 82: 1256-1256. DOI: 10.1158/1538-7445.am2022-1256.
• Abstract 2027: Spatial omics and multiplexed imaging to discover new biomarkers of response or resistance to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC)Moutafi M, Martinez-Morilla S, Garcia-Milian R, Aung T, Vathiotis I, Gavrielatou N, Xirou V, Salichos L, Rimm D. Abstract 2027: Spatial omics and multiplexed imaging to discover new biomarkers of response or resistance to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC). Cancer Research 2022, 82: 2027-2027. DOI: 10.1158/1538-7445.am2022-2027.
• Abstract 2028: Spatially resolved proteomic profiling identifies tumor cell CD44 as a novel indicative biomarker of sensitivity to PD-1 axis blockade in advanced non-small cell lung cancer (NSCLC)Moutafi M, Molero M, Martinez-Morilla S, Baena J, Vathiotis I, Gavrielatou N, Castro L, Ruiz de Garibay G, Adradas V, Orive D, Valencia K, Galvo A, Montuenga L, Ponce S, Schalper K, Paz-Ares L, Rimm D, Zugazagoitia J. Abstract 2028: Spatially resolved proteomic profiling identifies tumor cell CD44 as a novel indicative biomarker of sensitivity to PD-1 axis blockade in advanced non-small cell lung cancer (NSCLC). Cancer Research 2022, 82: 2028-2028. DOI: 10.1158/1538-7445.am2022-2028.
• Abstract 1229: miRNA and response to trastuzumabCosentino G, Pizzamiglio S, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Cosimo S, Iorio M. Abstract 1229: miRNA and response to trastuzumab. Cancer Research 2022, 82: 1229-1229. DOI: 10.1158/1538-7445.am2022-1229.
• Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.
• Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements.Blenman K, Fanucci K, Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Pusztai L. Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements. Journal Of Clinical Oncology 2022, 40: 594-594. DOI: 10.1200/jco.2022.40.16_suppl.594.
• Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Psyrri A, Rimm D. Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2022, 40: 6050-6050. DOI: 10.1200/jco.2022.40.16_suppl.6050.
• Development of an immunohistochemical assay for Siglec-15Shafi S, Aung TN, Robbins C, Zugazagoitia J, Vathiotis I, Gavrielatou N, Yaghoobi V, Fernandez A, Niu S, Liu LN, Cusumano ZT, Leelatian N, Cole K, Wang H, Homer R, Herbst RS, Langermann S, Rimm DL. Development of an immunohistochemical assay for Siglec-15. Laboratory Investigation 2022, 102: 771-778. PMID: 35459795, PMCID: PMC9253057, DOI: 10.1038/s41374-022-00785-9.
• Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profilingVesely M, Martinez-Morilla S, Gehlhausen JR, McNiff JM, Whang PG, Rimm D, Ko CJ. Not all well-differentiated cutaneous squamous cell carcinomas are equal: Tumors with disparate biologic behavior have differences in protein expression via digital spatial profiling. Journal Of The American Academy Of Dermatology 2022, 87: 695-698. PMID: 35398219, DOI: 10.1016/j.jaad.2022.03.057.
• Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research 2022, 28: 2587-2597. PMID: 35377948, PMCID: PMC9464605, DOI: 10.1158/1078-0432.ccr-21-3215.
• Examination of Low ERBB2 Protein Expression in Breast Cancer TissueFernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology 2022, 8: 1-4. PMID: 35113160, PMCID: PMC8814969, DOI: 10.1001/jamaoncol.2021.7239.
• Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivorsDieli-Conwright CM, Harrigan M, Cartmel B, Chagpar A, Bai Y, Li FY, Rimm DL, Pusztai L, Lu L, Sanft T, Irwin ML. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Npj Breast Cancer 2022, 8: 29. PMID: 35256599, PMCID: PMC8901848, DOI: 10.1038/s41523-022-00396-z.
• Inhibition of renalase drives tumour rejection by promoting T cell activationGuo X, Jessel S, Qu R, Kluger Y, Chen TM, Hollander L, Safirstein R, Nelson B, Cha C, Bosenberg M, Jilaveanu LB, Rimm D, Rothlin CV, Kluger HM, Desir GV. Inhibition of renalase drives tumour rejection by promoting T cell activation. European Journal Of Cancer 2022, 165: 81-96. PMID: 35219026, PMCID: PMC8940682, DOI: 10.1016/j.ejca.2022.01.002.
• Abstract P1-02-02: Examination of low Her2 expression in breast cancerFernandez A, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns J, Kuba M, Ly A, Podoll M, Rabe K, Sanders M, Singh K, Snir O, Soong R, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm D. Abstract P1-02-02: Examination of low Her2 expression in breast cancer. Cancer Research 2022, 82: p1-02-02-p1-02-02. DOI: 10.1158/1538-7445.sabcs21-p1-02-02.
• Abstract P4-03-01: Budding Tumorigenesis: A novel proposed model for breast cancer tumorigenesisYaghoobi V, Aung T, Moutafi M, Cooke T, Rimm D. Abstract P4-03-01: Budding Tumorigenesis: A novel proposed model for breast cancer tumorigenesis. Cancer Research 2022, 82: p4-03-01-p4-03-01. DOI: 10.1158/1538-7445.sabcs21-p4-03-01.
• Abstract P5-13-26: The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO studyIorio M, Pizzamiglio S, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Cosimo S. Abstract P5-13-26: The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study. Cancer Research 2022, 82: p5-13-26-p5-13-26. DOI: 10.1158/1538-7445.sabcs21-p5-13-26.
• Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2022, 8: 17. PMID: 35115541, PMCID: PMC8814070, DOI: 10.1038/s41523-022-00392-3.
• CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppressionZhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Science Translational Medicine 2022, 14: eabf5473. PMID: 35108062, PMCID: PMC9003667, DOI: 10.1126/scitranslmed.abf5473.
• Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung CancerGavrielatou N, Liu Y, Vathiotis I, Zugazagoitia J, Aung TN, Shafi S, Fernandez A, Schalper K, Psyrri A, Rimm DL. Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer. Clinical Cancer Research 2022, 28: clincanres.2649.2021. PMID: 34686497, PMCID: PMC8776595, DOI: 10.1158/1078-0432.ccr-21-2649.
• The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ PatientsTrant A, Chagpar A, Wei W, Neumeister V, Rimm D, Stavris K, Lurie B, Frederick C, Andrejeva L, Raghu M, Killelea B, Horowitz N, Lannin D, Knill-Selby E, Sturrock T, Hofstatter E. The Effect of Black Cohosh on Ki67 expression and Tumor Volume: A Pilot Study of Ductal Carcinoma in Situ Patients. Integrative Cancer Therapies 2022, 21: 15347354221137290. PMID: 36444764, PMCID: PMC9716631, DOI: 10.1177/15347354221137290.
• What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO studyPizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El‐abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV. What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine 2021, 11: 332-339. PMID: 34921525, PMCID: PMC8729061, DOI: 10.1002/cam4.4449.
• Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control studyYaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O’Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study. Breast Cancer Research 2021, 23: 113. PMID: 34906209, PMCID: PMC8670126, DOI: 10.1186/s13058-021-01493-w.
• Determination of the number of observers needed to evaluate a subjective test and its application in two PD‐L1 studiesHan G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Determination of the number of observers needed to evaluate a subjective test and its application in two PD‐L1 studies. Statistics In Medicine 2021, 41: 1361-1375. PMID: 34897773, PMCID: PMC10243718, DOI: 10.1002/sim.9282.
• The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupEl Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer 2021, 7: 150. PMID: 34853355, PMCID: PMC8636568, DOI: 10.1038/s41523-021-00346-1.
• Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility studyZerdes I, Simonetti M, Matikas A, Harbers L, Acs B, Boyaci C, Zhang N, Salgkamis D, Agartz S, Moreno-Ruiz P, Bai Y, Rimm DL, Hartman J, Mezheyeuski A, Bergh J, Crosetto N, Foukakis T. Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. Npj Breast Cancer 2021, 7: 144. PMID: 34799582, PMCID: PMC8604966, DOI: 10.1038/s41523-021-00352-3.
• Artificial intelligence applied to breast pathologyYousif M, van Diest PJ, Laurinavicius A, Rimm D, van der Laak J, Madabhushi A, Schnitt S, Pantanowitz L. Artificial intelligence applied to breast pathology. Virchows Archiv 2021, 480: 191-209. PMID: 34791536, DOI: 10.1007/s00428-021-03213-3.
• Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinomaFisk JN, Mahal AR, Dornburg A, Gaffney SG, Aneja S, Contessa JN, Rimm D, Yu JB, Townsend JP. Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters 2021, 526: 346-351. PMID: 34780851, PMCID: PMC8702484, DOI: 10.1016/j.canlet.2021.11.011.
• 52 Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI)Ptacek J, Vesely M, Rimm D, Hav M, Aksoy M, Crow A, Finn J. 52 Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI). Journal For ImmunoTherapy Of Cancer 2021, 9: a59-a59. DOI: 10.1136/jitc-2021-sitc2021.052.
• 240 Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profilingMoutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung T, Yaghoobi V, Fernandez A, Fraile J, Schalper K, Rimm D. 240 Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling. Journal For ImmunoTherapy Of Cancer 2021, 9: a258-a258. DOI: 10.1136/jitc-2021-sitc2021.240.
• Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic CancerMacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, Driscoll K, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers 2021, 13: 5501. PMID: 34771664, PMCID: PMC8583434, DOI: 10.3390/cancers13215501.
• Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working GroupVan Bockstal MR, Cooks M, Nederlof I, Brinkhuis M, Dutman A, Koopmans M, Kooreman L, van der Vegt B, Verhoog L, Vreuls C, Westenend P, Kok M, van Diest PJ, Nauwelaers I, Laudus N, Denkert C, Rimm D, Siziopikou KP, Ely S, Zardavas D, Roberts M, Floris G, Hartman J, Acs B, Peeters D, Bartlett JMS, Dequeker E, Salgado R, Giudici F, Michiels S, Horlings H, van Deurzen CHM. Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers 2021, 13: 4910. PMID: 34638394, PMCID: PMC8507620, DOI: 10.3390/cancers13194910.
• Standardization of PD-L1 immunohistochemistryMartinez-Morilla S, Moutafi M, Rimm DL. Standardization of PD-L1 immunohistochemistry. Modern Pathology 2021, 35: 294-295. PMID: 34508229, PMCID: PMC8860739, DOI: 10.1038/s41379-021-00917-4.
• Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancerFarahmand S, Fernandez AI, Ahmed FS, Rimm DL, Chuang JH, Reisenbichler E, Zarringhalam K. Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. Modern Pathology 2021, 35: 44-51. PMID: 34493825, PMCID: PMC10221954, DOI: 10.1038/s41379-021-00911-w.
• 1055P Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanomaChatziioannou E, Rossner J, Niessner H, Forchhammer S, Bonzheim I, Garbe C, Flatz L, Eigentler T, Aung T, Rimm D, Sinnberg T, Amaral T. 1055P Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanoma. Annals Of Oncology 2021, 32: s880-s881. DOI: 10.1016/j.annonc.2021.08.1440.
• Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancerVathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clinical Cancer Research 2021, 27: 6156-6163. PMID: 34465600, PMCID: PMC8595766, DOI: 10.1158/1078-0432.ccr-21-2103.
• High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior PrognosisLi P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis. Frontiers In Oncology 2021, 11: 701492. PMID: 34527580, PMCID: PMC8435777, DOI: 10.3389/fonc.2021.701492.
• Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLCDoroshow DB, Wei W, Gupta S, Zugazagoitia J, Robbins C, Adamson B, Rimm DL. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. Journal Of Thoracic Oncology 2021, 16: 2139-2143. PMID: 34455068, PMCID: PMC8612948, DOI: 10.1016/j.jtho.2021.07.032.
• Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) StudyTaube JM, Roman K, Engle EL, Wang C, Ballesteros-Merino C, Jensen SM, McGuire J, Jiang M, Coltharp C, Remeniuk B, Wistuba I, Locke D, Parra ER, Fox BA, Rimm DL, Hoyt C. Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. Journal For ImmunoTherapy Of Cancer 2021, 9: e002197. PMID: 34266881, PMCID: PMC8286792, DOI: 10.1136/jitc-2020-002197.
• Abstract 339: Resistance to trastuzumab is associated with alpha-smooth muscle actin expression in the stroma of patients with HER2+ breast cancerVathiotis I, Moutafi M, Divakar P, Aung T, Fernandez A, Yaghoobi V, Shafi S, Syrigos K, Fountzilas G, Pusztai L, Warren S, Rimm D. Abstract 339: Resistance to trastuzumab is associated with alpha-smooth muscle actin expression in the stroma of patients with HER2+ breast cancer. Cancer Research 2021, 81: 339-339. DOI: 10.1158/1538-7445.am2021-339.
• Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer PhenotypesApostolidi M, Vathiotis IA, Muthusamy V, Gaule P, Gassaway BM, Rimm DL, Rinehart J. Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes. Cancer Research 2021, 81: 4346-4359. PMID: 34185676, PMCID: PMC8373815, DOI: 10.1158/0008-5472.can-20-4190.
• Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockadeBerry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, Jessel S, Doyle J, Signer D, Wilton R, Roskes JS, Eminizer M, Park S, Sunshine JC, Jaffee EM, Baras A, De Marzo AM, Topalian SL, Kluger H, Cope L, Lipson EJ, Danilova L, Anders RA, Rimm DL, Pardoll DM, Szalay AS, Taube JM. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science 2021, 372 PMID: 34112666, PMCID: PMC8709533, DOI: 10.1126/science.aba2609.
• PD-L1 Expression Scoring: Non-Interchangeable, Non-Interpretable, Neither, or BothGavrielatou N, Shafi S, Gaule P, Rimm DL. PD-L1 Expression Scoring: Non-Interchangeable, Non-Interpretable, Neither, or Both. Journal Of The National Cancer Institute 2021, 113: djab109-. PMID: 34097056, PMCID: PMC8634453, DOI: 10.1093/jnci/djab109.
• An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast CancerBai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, Bosch A, Ehinger A, Nimeus E, Hartman J, Acs B, Rimm DL. An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. Clinical Cancer Research 2021, 27: clincanres.0325.2021. PMID: 34088723, PMCID: PMC8530841, DOI: 10.1158/1078-0432.ccr-21-0325.
• Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modalityVathiotis IA, Yang Z, Reeves J, Toki M, Aung TN, Wong PF, Kluger H, Syrigos KN, Warren S, Rimm DL. Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. Npj Precision Oncology 2021, 5: 45. PMID: 34050252, PMCID: PMC8163775, DOI: 10.1038/s41698-021-00184-1.
• Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors.Dieli-Conwright C, Harrigan M, Cartmel B, Chagpar A, Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e12501-e12501. DOI: 10.1200/jco.2021.39.15_suppl.e12501.
• Characterization of the tumor immune microenvironment of triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).Blenman K, Marczyk M, Qing T, O'Meara T, Yaghoobi V, Pelekanou V, Bai Y, Reisenbichler E, Li X, Gunasekharan V, Ibrahim E, Rimm D, Pusztai L, Cole K. Characterization of the tumor immune microenvironment of triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA). Journal Of Clinical Oncology 2021, 39: 564-564. DOI: 10.1200/jco.2021.39.15_suppl.564.
• Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC).Psyrri A, Moutafi M, Koliou G, Papaxoinis G, Gavrielatou N, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Fernandez A, Yaghoobi V, Shafi S, Vathiotis I, Aung T, Gkolfinopoulos S, Foukas P, Fountzilas G, Rimm D. Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2021, 39: 6064-6064. DOI: 10.1200/jco.2021.39.15_suppl.6064.
• Putting the Microenvironment into the Immunotherapy Companion DiagnosticMoutafi M, Rimm DL. Putting the Microenvironment into the Immunotherapy Companion Diagnostic. Clinical Cancer Research 2021, 27: 3812-3814. PMID: 33986024, DOI: 10.1158/1078-0432.ccr-21-1238.
• BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG CohortVassilakopoulou M, Won M, Curran WJ, Souhami L, Prados MD, Langer CJ, Rimm DL, Hanna JA, Neumeister VM, Melian E, Diaz AZ, Atkins JN, Komarnicky LT, Schultz CJ, Howard SP, Zhang P, Dicker AP, Knisely JPS. BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort. Oncology 2021, 99: 580-588. PMID: 33957633, PMCID: PMC8491475, DOI: 10.1159/000516168.
• Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.
• STING enhances cell death through regulation of reactive oxygen species and DNA damageHayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 2021, 12: 2327. PMID: 33875663, PMCID: PMC8055995, DOI: 10.1038/s41467-021-22572-8.
• PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical dataMoutafi M, Economopoulou P, Rimm D, Psyrri A. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. Oral Oncology 2021, 117: 105292. PMID: 33862558, DOI: 10.1016/j.oraloncology.2021.105292.
• Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancerMoutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross JS, Syrigos K, Wei W, Pusztai L, Rimm DL, Vathiotis IA. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. Journal For ImmunoTherapy Of Cancer 2021, 9: e002230. PMID: 33833050, PMCID: PMC8039214, DOI: 10.1136/jitc-2020-002230.
• An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracyPerincheri S, Levi AW, Celli R, Gershkovich P, Rimm D, Morrow JS, Rothrock B, Raciti P, Klimstra D, Sinard J. An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy. Modern Pathology 2021, 34: 1588-1595. PMID: 33782551, PMCID: PMC8295034, DOI: 10.1038/s41379-021-00794-x.
• Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology AssociationLara H, Li Z, Abels E, Aeffner F, Bui MM, ElGabry EA, Kozlowski C, Montalto MC, Parwani AV, Zarella MD, Bowman D, Rimm D, Pantanowitz L. Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association. Applied Immunohistochemistry & Molecular Morphology 2021, 29: 479-493. PMID: 33734106, PMCID: PMC8354563, DOI: 10.1097/pai.0000000000000930.
• Quantitative Assessment of CD200 and CD200R Expression in Lung CancerVathiotis IA, MacNeil T, Zugazagoitia J, Syrigos KN, Aung TN, Gruver AM, Vaillancourt P, Hughes I, Hinton S, Driscoll K, Rimm DL. Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer. Cancers 2021, 13: 1024. PMID: 33804482, PMCID: PMC7957629, DOI: 10.3390/cancers13051024.
• P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer PatientsMoutafi M, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross J, Syrigos K, Wei W, Pusztai L, Rimm D, Vathiotis I. P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients. Journal Of Thoracic Oncology 2021, 16: s405-s406. DOI: 10.1016/j.jtho.2021.01.671.
• Abstract PO-003: Deep learning identifies conserved pan-cancer tumor featuresNoorbakhsh J, Farahmand S, Foroughi pour A, Namburi S, Caruana D, Rimm D, Soltanieh-ha M, Zarringhalam K, Chuang J. Abstract PO-003: Deep learning identifies conserved pan-cancer tumor features. Clinical Cancer Research 2021, 27: po-003-po-003. DOI: 10.1158/1557-3265.adi21-po-003.
• Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung CancerDatar IJ, Hauc SC, Desai S, Gianino N, Henick B, Liu Y, Syrigos K, Rimm DL, Kavathas P, Ferrone S, Schalper KA. Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer. Clinical Cancer Research 2021, 27: 2837-2847. PMID: 33602682, PMCID: PMC8734284, DOI: 10.1158/1078-0432.ccr-20-3655.
• Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancersRozenblit M, Huang R, Danziger N, Alexander B, Ramkissoon S, Blenman K, Ross J, Rimm D, Pusztai L. Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Cancer Research 2021, 81: ps5-08-ps5-08. DOI: 10.1158/1538-7445.sabcs20-ps5-08.
• Abstract PS2-03: Comparison of pathologist reads of sp142 and sp263 with quantitative measurement of protein and mRNA in triple negative breast cancerGupta S, Yaghoobi V, Fernandez A, McCann L, Weidler J, Bates M, Reisenbichler E, Rimm D. Abstract PS2-03: Comparison of pathologist reads of sp142 and sp263 with quantitative measurement of protein and mRNA in triple negative breast cancer. Cancer Research 2021, 81: ps2-03-ps2-03. DOI: 10.1158/1538-7445.sabcs20-ps2-03.
• PD-L1 as a biomarker of response to immune-checkpoint inhibitorsDoroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology 2021, 18: 345-362. PMID: 33580222, DOI: 10.1038/s41571-021-00473-5.
• Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerFoldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer. Npj Breast Cancer 2021, 7: 9. PMID: 33558513, PMCID: PMC7870853, DOI: 10.1038/s41523-021-00219-7.
• A new tool for technical standardization of the Ki67 immunohistochemical assayAung TN, Acs B, Warrell J, Bai Y, Gaule P, Martinez-Morilla S, Vathiotis I, Shafi S, Moutafi M, Gerstein M, Freiberg B, Fulton R, Rimm DL. A new tool for technical standardization of the Ki67 immunohistochemical assay. Modern Pathology 2021, 34: 1261-1270. PMID: 33536573, PMCID: PMC8222064, DOI: 10.1038/s41379-021-00745-6.
• Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanomaMoore MR, Friesner ID, Rizk EM, Fullerton BT, Mondal M, Trager MH, Mendelson K, Chikeka I, Kurc T, Gupta R, Rohr BR, Robinson EJ, Acs B, Chang R, Kluger H, Taback B, Geskin LJ, Horst B, Gardner K, Niedt G, Celebi JT, Gartrell-Corrado RD, Messina J, Ferringer T, Rimm DL, Saltz J, Wang J, Vanguri R, Saenger YM. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Scientific Reports 2021, 11: 2809. PMID: 33531581, PMCID: PMC7854647, DOI: 10.1038/s41598-021-82305-1.
• Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass CytometryMultiplex Discovery with Imaging Mass CytometryMartinez-Morilla S, Villarroel-Espindola F, Wong PF, Toki MI, Aung TN, Pelekanou V, Bourke-Martin B, Schalper KA, Kluger HM, Rimm DL. Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass CytometryMultiplex Discovery with Imaging Mass Cytometry. Clinical Cancer Research 2021, 27: 1987-1996. PMID: 33504554, PMCID: PMC8026677, DOI: 10.1158/1078-0432.ccr-20-3340.
• Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.Yeung J, Yaghoobi V, Aung TN, Vesely MD, Zhang T, Gaule P, Gunel M, Rimm DL, Chen L. Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. Journal Of Neuropathology & Experimental Neurology 2021, 80: 150-159. PMID: 33393633, DOI: 10.1093/jnen/nlaa152.
• Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced MelanomaJohannet P, Coudray N, Donnelly DM, Jour G, Illa-Bochaca I, Xia Y, Johnson DB, Wheless L, Patrinely JR, Nomikou S, Rimm DL, Pavlick AC, Weber JS, Zhong J, Tsirigos A, Osman I. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. Clinical Cancer Research 2021, 27: 131-140. PMID: 33208341, PMCID: PMC7785656, DOI: 10.1158/1078-0432.ccr-20-2415.
• Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at YaleMorrow JS, Gershkovich P, Gibson J, Gilshannon M, Kowalski D, Levi AW, Nguyen DX, Rimm DL, Xu ML, Sinard J. Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale. Academic Pathology 2021, 8: 23742895211047985. PMID: 34646939, PMCID: PMC8504692, DOI: 10.1177/23742895211047985.
• Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapyMartinez-Morilla S, Zugazagoitia J, Wong PF, Kluger HM, Rimm DL. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy. OncoImmunology 2020, 10: 1864909. PMID: 33457084, PMCID: PMC7781756, DOI: 10.1080/2162402x.2020.1864909.
• Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working GroupNielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group. Journal Of The National Cancer Institute 2020, 113: djaa201-. PMID: 33369635, PMCID: PMC8487652, DOI: 10.1093/jnci/djaa201.
• Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological imagesNoorbakhsh J, Farahmand S, Foroughi pour A, Namburi S, Caruana D, Rimm D, Soltanieh-ha M, Zarringhalam K, Chuang JH. Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images. Nature Communications 2020, 11: 6367. PMID: 33311458, PMCID: PMC7733499, DOI: 10.1038/s41467-020-20030-5.
• Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancersRozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. Journal For ImmunoTherapy Of Cancer 2020, 8: e001558. PMID: 33239417, PMCID: PMC7689582, DOI: 10.1136/jitc-2020-001558.
• How current assay approval policies are leading to unintended imprecision medicineSalgado R, Bellizzi AM, Rimm D, Bartlett JMS, Nielsen T, Holger M, Laenkholm AV, Quinn C, Cserni G, Cunha IW, Alvarado-Cabrero I, Cree I. How current assay approval policies are leading to unintended imprecision medicine. The Lancet Oncology 2020, 21: 1399-1401. PMID: 33098760, DOI: 10.1016/s1470-2045(20)30592-1.
• A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective studyLu C, Bera K, Wang X, Prasanna P, Xu J, Janowczyk A, Beig N, Yang M, Fu P, Lewis J, Choi H, Schmid RA, Berezowska S, Schalper K, Rimm D, Velcheti V, Madabhushi A. A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study. The Lancet Digital Health 2020, 2: e594-e606. PMID: 33163952, PMCID: PMC7646741, DOI: 10.1016/s2589-7500(20)30225-9.
• PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast CancerAhmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, Rimm DL. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. Clinical Cancer Research 2020, 26: 5456-5461. PMID: 32709714, PMCID: PMC7572612, DOI: 10.1158/1078-0432.ccr-20-1303.
• Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistryMacNeil T, Vathiotis IA, Martinez-Morilla S, Yaghoobi V, Zugazagoitia J, Liu Y, Rimm DL. Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry. BioTechniques 2020, 69: 460-468. PMID: 32852223, PMCID: PMC7807291, DOI: 10.2144/btn-2020-0095.
• Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patientsYaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D, Blenman K. Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients. Cancer Research 2020, 80: 4973-4973. DOI: 10.1158/1538-7445.am2020-4973.
• Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLCLiu Y, Zugazagoitia J, Schalper K, Herbst R, Rimm D. Abstract 2002: Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC. Cancer Research 2020, 80: 2002-2002. DOI: 10.1158/1538-7445.am2020-2002.
• Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancerDing A, Villarroel-Espindola F, Ducler A, Henick B, Desai S, Gianino N, Zugazagoitia J, Rimm D, Robert A, Cruzalegui F, Ferré P, Herbst R, Sanmamed M, Chen L, Schalper K. Abstract 5525: VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer. Cancer Research 2020, 80: 5525-5525. DOI: 10.1158/1538-7445.am2020-5525.
• Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trialRediti M, Venet D, Rothé F, Qing T, Maetens M, Bradbury I, Izquierdo M, Cosimo S, Hilbers F, Bajji M, Harbeck N, Untch M, Rimm D, Chia S, Liu M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial. Cancer Research 2020, 80: 1998-1998. DOI: 10.1158/1538-7445.am2020-1998.
• Abstract 3095: Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signaturesVathiotis I, Reeves J, Toki M, Wong P, Kluger H, Aung T, Syrigos K, Warren S, Rimm D. Abstract 3095: Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures. Cancer Research 2020, 80: 3095-3095. DOI: 10.1158/1538-7445.am2020-3095.
• Abstract 2001: Biomarker discovery in immunotherapy-treated melanoma patients with imaging mass cytometryMartinez-Morilla S, Villarroel-Espindola F, Wong P, Kluger H, Toki M, Aung T, Pelekanou V, Bourke-Martin B, Rimm D. Abstract 2001: Biomarker discovery in immunotherapy-treated melanoma patients with imaging mass cytometry. Cancer Research 2020, 80: 2001-2001. DOI: 10.1158/1538-7445.am2020-2001.
• Abstract 937: Quantitative assessment of CD200 and CD200R expression in lung cancerVathiotis I, MacNeil T, Zugazagoitia J, Martinez-Morilla S, Ahmed F, Syrigos K, Gruver A, Driscoll K, Rimm D. Abstract 937: Quantitative assessment of CD200 and CD200R expression in lung cancer. Cancer Research 2020, 80: 937-937. DOI: 10.1158/1538-7445.am2020-937.
• Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial ProfilingZugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. Clinical Cancer Research 2020, 26: 4360-4368. PMID: 32253229, PMCID: PMC7442721, DOI: 10.1158/1078-0432.ccr-20-0175.
• Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast CancersO’Meara T, Marczyk M, Qing T, Yaghoobi V, Blenman K, Cole K, Pelekanou V, Rimm DL, Pusztai L. Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers. JCO Precision Oncology 2020, 4: po.19.00350. PMID: 32923897, PMCID: PMC7446500, DOI: 10.1200/po.19.00350.
• PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).Doroshow D, Wei W, Zugazagoitia J, Robbins C, Gupta S, Adamson B, Rimm D. PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2020, 38: 9539-9539. DOI: 10.1200/jco.2020.38.15_suppl.9539.
• Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.Gutierrez M, Hamid O, Shum E, Wise D, Balar A, Weber J, LoRusso P, Shafi S, Rimm D, Tolcher A, Basudhar D, Dujka M, Heller K. Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors. Journal Of Clinical Oncology 2020, 38: tps3166-tps3166. DOI: 10.1200/jco.2020.38.15_suppl.tps3166.
• The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validationTaube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB, . The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. Journal For ImmunoTherapy Of Cancer 2020, 8: e000155. PMID: 32414858, PMCID: PMC7239569, DOI: 10.1136/jitc-2019-000155.
• Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancerKos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer 2020, 6: 17. PMID: 32411819, PMCID: PMC7217863, DOI: 10.1038/s41523-020-0156-0.
• Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupAmgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer 2020, 6: 16. PMID: 32411818, PMCID: PMC7217824, DOI: 10.1038/s41523-020-0154-2.
• Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trialsHudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer 2020, 6: 15. PMID: 32436923, PMCID: PMC7217941, DOI: 10.1038/s41523-020-0155-1.
• Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer 2020, 6: 16. PMID: 33574288, DOI: 10.1038/s41523-020-0154-2.
• Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 2020, 6: 17. PMID: 33574291, DOI: 10.1038/s41523-020-0156-0.
• Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer 2020, 6: 15. PMID: 33574324, DOI: 10.1038/s41523-020-0155-1.
• Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges.McKean WB, Moser JC, Rimm D, Hu-Lieskovan S. Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society Of Clinical Oncology Educational Book 2020, 40: e275-e291. PMID: 32453632, DOI: 10.1200/edbk_280571.
• Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancerReisenbichler ES, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison BT, Kuba MG, Ly A, Miller D, Podoll M, Roden AC, Singh K, Sanders MA, Wei S, Wen H, Pelekanou V, Yaghoobi V, Ahmed F, Pusztai L, Rimm DL. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Modern Pathology 2020, 33: 1746-1752. PMID: 32300181, PMCID: PMC8366569, DOI: 10.1038/s41379-020-0544-x.
• The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practiceGonzalez‐Ericsson P, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Lænkholm A, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent‐Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta‐Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault‐Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, Bairi K, Harbeck N, Cimino‐Mathews A, Sotiriou C, Adams S, Liu S, Loibl S, Chen I, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon‐Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M, Group I. The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. The Journal Of Pathology 2020, 250: 667-684. PMID: 32129476, DOI: 10.1002/path.5406.
• Digital quantitative assessment of PD-L1 using digital spatial profilingGupta S, Zugazagoitia J, Martinez-Morilla S, Fuhrman K, Rimm DL. Digital quantitative assessment of PD-L1 using digital spatial profiling. Laboratory Investigation 2020, 100: 1311-1317. PMID: 32249818, PMCID: PMC7502436, DOI: 10.1038/s41374-020-0424-5.
• Advances in quantitative immunohistochemistry and their contribution to breast cancerYaghoobi V, Martinez-Morilla S, Liu Y, Charette L, Rimm DL, Harigopal M. Advances in quantitative immunohistochemistry and their contribution to breast cancer. Expert Review Of Molecular Diagnostics 2020, 20: 509-522. PMID: 32178550, DOI: 10.1080/14737159.2020.1743178.
• Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scoresDing R, Prasanna P, Corredor G, Lu C, Velu P, Le K, Leo P, Beig N, Velcheti V, Rimm D, Schalper K, Madabhushi A. Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scores. 2020, 2. DOI: 10.1117/12.2549588.
• Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group studyAcs B, Leung S, Kidwell K, Arun I, Augulis R, Badve S, Bai Y, Bane A, Bartlett J, Bayani J, Bigras G, Blank A, Borgquist S, Buikema H, Chang M, Dietz R, Dodson A, Ehinger A, Fineberg S, Focke C, Gao D, Gown A, Gutierrez C, Hartman J, Hugh J, Kos Z, Lænkholm A, Laurinavicius A, Levenson R, Mahboubi-Ardakani R, Mastropasqua M, Moriya T, Nofech-Mozes S, Osborne C, Pantanowitz L, Penault-Llorca F, Piper T, Quintayo M, Rau T, Reinhard S, Robertson S, Sakatani T, Salgado R, Spears M, Starczynski J, Sugie T, van der Vegt B, Viale G, Virk S, Zabaglo L, Hayes D, Dowsett M, Nielsen T, Rimm D. Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study. Cancer Research 2020, 80: p5-02-01-p5-02-01. DOI: 10.1158/1538-7445.sabcs19-p5-02-01.
• Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello T, Blenman K, Rimm D, Silber A. Abstract PD1-01: Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Cancer Research 2020, 80: pd1-01-pd1-01. DOI: 10.1158/1538-7445.sabcs19-pd1-01.
• Abstract P3-08-12: An open source, automated tumor infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancerBai Y, Acs B, Zugazagoitia J, Martinez-Morilla S, Ahmed F, Rimm D. Abstract P3-08-12: An open source, automated tumor infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer. Cancer Research 2020, 80: p3-08-12-p3-08-12. DOI: 10.1158/1538-7445.sabcs19-p3-08-12.
• Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC)Blenman K, Li X, Marczyk M, O'Meara T, Yaghoobi V, Gunasekharan V, Park T, Rimm D, Pusztai L. Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC). Cancer Research 2020, 80: p3-09-05-p3-09-05. DOI: 10.1158/1538-7445.sabcs19-p3-09-05.
• Abstract P4-10-14: Quantitative assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer (TNBC)Ahmed F, McGuire J, Gaule P, Blenman K, Pusztai L, Rimm D. Abstract P4-10-14: Quantitative assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer (TNBC). Cancer Research 2020, 80: p4-10-14-p4-10-14. DOI: 10.1158/1538-7445.sabcs19-p4-10-14.
• Abstract PD5-01: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays in triple negative breast cancerReisenbichler E, Han G, Pelekanou V, Yaghoobi V, Ahmed F, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison B, Kuba M, Ly A, Miller D, Podoll M, Roden A, Sanders M, Singh K, Wei S, Wen H, Pusztai L, Rimm D. Abstract PD5-01: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays in triple negative breast cancer. Cancer Research 2020, 80: pd5-01-pd5-01. DOI: 10.1158/1538-7445.sabcs19-pd5-01.
• Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade TherapyLiu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger S, Herbst RS, Schalper KA, Rimm DL. Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clinical Cancer Research 2020, 26: 970-977. PMID: 31615933, PMCID: PMC7024671, DOI: 10.1158/1078-0432.ccr-19-1040.
• Association between low estrogen receptor positive breast cancer and staining performanceCaruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES. Association between low estrogen receptor positive breast cancer and staining performance. Npj Breast Cancer 2020, 6: 5. PMID: 32047851, PMCID: PMC7002746, DOI: 10.1038/s41523-020-0146-2.
• Association between low estrogen receptor positive breast cancer and staining performance.Caruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES. Association between low estrogen receptor positive breast cancer and staining performance. NPJ Breast Cancer 2020, 6: 5. PMID: 33536443, DOI: 10.1038/s41523-020-0146-2.
• Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase InhibitionGale M, Li Y, Cao J, Liu ZZ, Holmbeck MA, Zhang M, Lang SM, Wu L, Do Carmo M, Gupta S, Aoshima K, DiGiovanna MP, Stern DF, Rimm DL, Shadel GS, Chen X, Yan Q. Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition. Cancer Research 2020, 80: 524-535. PMID: 31690671, PMCID: PMC7002225, DOI: 10.1158/0008-5472.can-18-3985.
• Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline UpdateAllison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Archives Of Pathology & Laboratory Medicine 2020, 144: 545-563. PMID: 31928354, DOI: 10.5858/arpa.2019-0904-sa.
• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal Of Clinical Oncology 2020, 38: 1346-1366. PMID: 31928404, DOI: 10.1200/jco.19.02309.
• An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanomaAcs B, Ahmed FS, Gupta S, Wong P, Gartrell RD, Sarin Pradhan J, Rizk EM, Gould Rothberg B, Saenger YM, Rimm DL. An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. Nature Communications 2019, 10: 5440. PMID: 31784511, PMCID: PMC6884485, DOI: 10.1038/s41467-019-13043-2.
• Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune responseSahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R, Mehta S, Reshetnyak YK, Bahal R, Fiorina P, Glazer PM, Rimm DL, Fernández-Hernando C, Suárez Y. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. Journal Of Clinical Investigation 2019, 129: 5518-5536. PMID: 31710308, PMCID: PMC6877327, DOI: 10.1172/jci127125.
• Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and DeathKulkarni PM, Robinson EJ, Pradhan J, Gartrell-Corrado RD, Rohr BR, Trager MH, Geskin LJ, Kluger HM, Wong PF, Acs B, Rizk EM, Yang C, Mondal M, Moore MR, Osman I, Phelps R, Horst BA, Chen ZS, Ferringer T, Rimm DL, Wang J, Saenger YM. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. Clinical Cancer Research 2019, 26: 1126-1134. PMID: 31636101, PMCID: PMC8142811, DOI: 10.1158/1078-0432.ccr-19-1495.
• Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung CancerZugazagoitia J, Liu Y, Toki M, McGuire J, Ahmed FS, Henick BS, Gupta R, Gettinger S, Herbst R, Schalper KA, Rimm DL. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: 2084-2096. PMID: 31605795, PMCID: PMC6951804, DOI: 10.1016/j.jtho.2019.09.014.
• 185PD Immunological differences between immune-rich estrogen receptor-positive and -negative breast cancersO’Meara T, Marczyk M, Blenman K, Yaghoobi V, Pelenkanou V, Rimm D, Pusztai L. 185PD Immunological differences between immune-rich estrogen receptor-positive and -negative breast cancers. Annals Of Oncology 2019, 30: v60-v61. DOI: 10.1093/annonc/mdz240.011.
• MA15.05 Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLCVelcheti V, Lu C, Bera K, Wang X, Fu P, Yang M, Rimm D, Schalper K, Madabhushi A. MA15.05 Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLC. Journal Of Thoracic Oncology 2019, 14: s310. DOI: 10.1016/j.jtho.2019.08.622.
• MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung CancerWang X, Barrera C, Bera K, Lu C, Feldman M, Schalper K, Rimm D, Velcheti V, Madabhushi A. MA25.02 Arrangement and Architecture of Tumor-Infiltrating Lymphocyte on H&E Slides Predict OS in Nivolumab Treated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2019, 14: s350-s351. DOI: 10.1016/j.jtho.2019.08.710.
• Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanomaGupta S, McCann L, Chan YGY, Lai EW, Wei W, Wong PF, Smithy JW, Weidler J, Rhees B, Bates M, Kluger HM, Rimm DL. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 254. PMID: 31533832, PMCID: PMC6751819, DOI: 10.1186/s40425-019-0731-9.
• High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial ProfilingToki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL. High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research 2019, 25: 5503-5512. PMID: 31189645, PMCID: PMC6744974, DOI: 10.1158/1078-0432.ccr-19-0104.
• Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancerGupta S, Neumeister V, McGuire J, Song YS, Acs B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL, Bossuyt V. Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. Npj Breast Cancer 2019, 5: 28. PMID: 31482108, PMCID: PMC6715641, DOI: 10.1038/s41523-019-0122-x.
• Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarrayMartinez-Morilla S, McGuire J, Gaule P, Moore L, Acs B, Cougot D, Gown AM, Yaziji H, Wang WL, Cartun RW, Hornick JL, Sholl LM, Qiu J, Mino-Kenudson M, Yi ES, Beasley MB, Merrick DT, Ambaye AB, Zhang ZJ, Walker J, Rimm DL. Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Laboratory Investigation 2019, 100: 4-15. PMID: 31409885, PMCID: PMC6920558, DOI: 10.1038/s41374-019-0295-9.
• Artificial intelligence in digital pathology — new tools for diagnosis and precision oncologyBera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology. Nature Reviews Clinical Oncology 2019, 16: 703-715. PMID: 31399699, PMCID: PMC6880861, DOI: 10.1038/s41571-019-0252-y.
• “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracyTorlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, Fujimoto D, Han G, Hirsch FR, Ilie M, Ionescu D, Li C, Munari E, Okuda K, Ratcliffe MJ, Rimm DL, Ross C, Røge R, Scheel AH, Soo RA, Swanson PE, Tretiakova M, To KF, Vainer GW, Wang H, Xu Z, Zielinski D, Tsao MS. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology 2019, 33: 4-17. PMID: 31383961, PMCID: PMC6927905, DOI: 10.1038/s41379-019-0327-4.
• Immunotherapy in Non–Small Cell Lung Cancer: Facts and HopesDoroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research 2019, 25: 4592-4602. PMID: 30824587, PMCID: PMC6679805, DOI: 10.1158/1078-0432.ccr-18-1538.
• Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell AnalysisDatar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías L, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical Cancer Research 2019, 25: 4663-4673. PMID: 31053602, PMCID: PMC7444693, DOI: 10.1158/1078-0432.ccr-18-4142.
• Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint BlockadeLu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, Hoyt C, Pardoll DM, Danilova L, Taube JM. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. JAMA Oncology 2019, 5: 1195-1204. PMID: 31318407, PMCID: PMC6646995, DOI: 10.1001/jamaoncol.2019.1549.
• Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanomaWong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 194. PMID: 31337426, PMCID: PMC6651990, DOI: 10.1186/s40425-019-0675-0.
• Abstract 2842: Vesal YaghoobiYaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D. Abstract 2842: Vesal Yaghoobi. Cancer Research 2019, 79: 2842-2842. DOI: 10.1158/1538-7445.am2019-2842.
• Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytesToki M, Zugazagoitia J, Altan M, Liu L, Mani N, Liu Y, Syrigos K, Chen L, Langermann S, Herbst R, Rimm D. Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes. 2019, 3151-3151. DOI: 10.1158/1538-7445.sabcs18-3151.
• Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytesToki M, Zugazagoitia J, Altan M, Liu L, Mani N, Liu Y, Syrigos K, Chen L, Langermann S, Herbst R, Rimm D. Abstract 3151: Quantitative measurement of Siglec-15 expression in non-small cell lung cancer and its association with PD-L1, B7-H4 and tumor infiltrating lymphocytes. Cancer Research 2019, 79: 3151-3151. DOI: 10.1158/1538-7445.am2019-3151.
• Abstract 3142: A CD274, PDCD1LG2, CD8A, and IRF1 multiplex in a closed system RT-qPCR panel and immunotherapy outcome in metastatic melanomaGupta S, McCann L, Chan Y, Lai E, Wong P, Smithy J, Weidler J, Rhees B, Bates M, Kluger H, Rimm D. Abstract 3142: A CD274, PDCD1LG2, CD8A, and IRF1 multiplex in a closed system RT-qPCR panel and immunotherapy outcome in metastatic melanoma. 2019, 3142-3142. DOI: 10.1158/1538-7445.sabcs18-3142.
• Abstract 3142: A CD274, PDCD1LG2, CD8A, and IRF1 multiplex in a closed system RT-qPCR panel and immunotherapy outcome in metastatic melanomaGupta S, McCann L, Chan Y, Lai E, Wong P, Smithy J, Weidler J, Rhees B, Bates M, Kluger H, Rimm D. Abstract 3142: A CD274, PDCD1LG2, CD8A, and IRF1 multiplex in a closed system RT-qPCR panel and immunotherapy outcome in metastatic melanoma. Cancer Research 2019, 79: 3142-3142. DOI: 10.1158/1538-7445.am2019-3142.
• Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patientsLiu Y, Zugazagoitia J, Henick B, Schalper K, Rimm D. Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients. 2019, 2674-2674. DOI: 10.1158/1538-7445.sabcs18-2674.
• Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patientsLiu Y, Zugazagoitia J, Henick B, Schalper K, Rimm D. Abstract 2674: Immune profiling of in NSCLC shows expression of PD-L1 in macrophages is better associated with outcomes than PD-L1 in tumor cells in PD-1 axis immunotherapy treated patients. Cancer Research 2019, 79: 2674-2674. DOI: 10.1158/1538-7445.am2019-2674.
• Abstract LB-318: Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE study): Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflowHoyt C, Roman K, Engle L, Wang C, Ballesteros-Merino C, Jensen S, McGuire J, Zheng Y, Coltharp C, Jiang M, Lucas J, Parra E, Wistuba I, Locke D, Fox B, Rimm D, Taube J. Abstract LB-318: Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE study): Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow. 2019, lb-318-lb-318. DOI: 10.1158/1538-7445.sabcs18-lb-318.
• Abstract LB-318: Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE study): Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflowHoyt C, Roman K, Engle L, Wang C, Ballesteros-Merino C, Jensen S, McGuire J, Zheng Y, Coltharp C, Jiang M, Lucas J, Parra E, Wistuba I, Locke D, Fox B, Rimm D, Taube J. Abstract LB-318: Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE study): Reproducibility assessment of an automated multiplexed immunofluorescence slide staining, imaging, and analysis workflow. Cancer Research 2019, 79: lb-318-lb-318. DOI: 10.1158/1538-7445.am2019-lb-318.
• Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancerRimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. Breast Cancer Research 2019, 21: 72. PMID: 31196152, PMCID: PMC6567382, DOI: 10.1186/s13058-019-1156-6.
• Corrections to “Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial”Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Corrections to “Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial”. Annals Of Oncology 2019, 30: 1018. PMID: 30624555, PMCID: PMC6594454, DOI: 10.1093/annonc/mdy530.
• Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).O'Meara T, Yaghoobi V, Blenman K, Pelekanou V, Silber A, Rimm D, Pusztai L. Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2019, 37: e14180-e14180. DOI: 10.1200/jco.2019.37.15_suppl.e14180.
• Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.Robinson E, Kulkarni P, Pradhan J, Gartrell R, Yang C, Rizk E, Acs B, Rohr B, Phelps R, Ferringer T, Horst B, Rimm D, Wang J, Saenger Y. Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning. Journal Of Clinical Oncology 2019, 37: 9577-9577. DOI: 10.1200/jco.2019.37.15_suppl.9577.
• Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass CytometryCarvajal-Hausdorf DE, Patsenker J, Stanton KP, Villarroel-Espindola F, Esch A, Montgomery RR, Psyrri A, Kalogeras KT, Kotoula V, Foutzilas G, Schalper KA, Kluger Y, Rimm DL. Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry. Clinical Cancer Research 2019, 25: 3054-3062. PMID: 30796036, PMCID: PMC6522272, DOI: 10.1158/1078-0432.ccr-18-2599.
• Phenotyping tumor infiltrating lymphocytes (PhenoTIL) on H&E tissue images: predicting recurrence in lung cancerBarrera C, Corredor G, Wang X, Schalper K, Rimm D, Velcheti V, Madabhushi A, Castro E. Phenotyping tumor infiltrating lymphocytes (PhenoTIL) on H&E tissue images: predicting recurrence in lung cancer. Progress In Biomedical Optics And Imaging 2019, 10956: 1095607-1095607-8. DOI: 10.1117/12.2513048.
• Addressing the dichotomy between individual and societal approaches to personalised medicine in oncologySalgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C, Bernards R, Bogaerts J, Canetta R, Sullivan R, Tejpar S, Lukinova N, Lyerly H, Moore H, Smith M, Yee L, DuBois R, Hahn W, Janne P, Solit D, Willman C, Rimm D, Bateman-House A, Makady A, Bergmann L, Nagai S, Thomas M, Cree I, Hegde P, Hopper S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Ingelman-Sundberg M, Nichols G, Maignen F, Besse B, Swierzewski R, Lambin P, Kiermaier A, Lacombe D, Lively T, Massard C, Caliguri M, Velculescu V, Foggi P, Hahn W, Lukinova N, Salgado R, Golfinopoulos V. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal Of Cancer 2019, 114: 128-136. PMID: 31060925, DOI: 10.1016/j.ejca.2019.03.025.
• Corrigendum to “Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma” [Oral Oncol. 86 (2018) 278–287]Hartman DJ, Ahmed F, Ferris RL, Rimm DL, Pantanowitz L. Corrigendum to “Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma” [Oral Oncol. 86 (2018) 278–287]. Oral Oncology 2019, 93: 129. PMID: 31053366, DOI: 10.1016/j.oraloncology.2019.04.016.
• False-positive pathology: improving reproducibility with the next generation of pathologistsMazer BL, Homer RJ, Rimm DL. False-positive pathology: improving reproducibility with the next generation of pathologists. Laboratory Investigation 2019, 99: 1260-1265. PMID: 31019290, DOI: 10.1038/s41374-019-0257-2.
• Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic MelanomaWong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman K, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clinical Cancer Research 2019, 25: 2442-2449. PMID: 30617133, PMCID: PMC6467753, DOI: 10.1158/1078-0432.ccr-18-2652.
• Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology CommitteeMoncur JT, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Kim AS. Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee. Archives Of Pathology & Laboratory Medicine 2019, 143: 1203-1211. PMID: 30969158, DOI: 10.5858/arpa.2018-0396-cp.
• A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non–Small Cell Lung CancerTaylor CR, Jadhav AP, Gholap A, Kamble G, Huang J, Gown A, Doshi I, Rimm DL. A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non–Small Cell Lung Cancer. Applied Immunohistochemistry & Molecular Morphology 2019, 27: 263-269. PMID: 30640753, DOI: 10.1097/pai.0000000000000737.
• 31. The PT alphabet soup: LDT, FDA, NGS, non-NGS, @#$!%Kim A, Bartley A, Bridge J, Devereaux K, Iafrate A, Jennings L, Kamel-Reid S, Keegan A, Lazar A, Lindeman N, Long T, Merker J, Moncur J, Montgomery N, Montgomery S, Nagarajan R, Oakley F, Portier B, Rai A, Rimm D, Rothberg P, Smail C, Surrey L, Vasalos P, Xian R. 31. The PT alphabet soup: LDT, FDA, NGS, non-NGS, @#$!%. Cancer Genetics 2019, 233: s13. DOI: 10.1016/j.cancergen.2019.04.037.
• Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). Journal For ImmunoTherapy Of Cancer 2019, 7: 65. PMID: 30850021, PMCID: PMC6408760, DOI: 10.1186/s40425-019-0540-1.
• Immune Checkpoint Inhibitor–Associated PericarditisAltan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL. Immune Checkpoint Inhibitor–Associated Pericarditis. Journal Of Thoracic Oncology 2019, 14: 1102-1108. PMID: 30851443, PMCID: PMC6617516, DOI: 10.1016/j.jtho.2019.02.026.
• Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapyWang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O’Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nature Medicine 2019, 25: 656-666. PMID: 30833750, PMCID: PMC7175920, DOI: 10.1038/s41591-019-0374-x.
• Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung CancerCorredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos K, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A. Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer. Clinical Cancer Research 2019, 25: 1526-1534. PMID: 30201760, PMCID: PMC6397708, DOI: 10.1158/1078-0432.ccr-18-2013.
• Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsLoi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM. Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research 2019, 25: 1437-1437. PMID: 30770496, DOI: 10.1158/1078-0432.ccr-18-4264.
• Abstract P4-02-01: Analytical validation of an automated digital scoring protocol for Ki67: International multicenter collaboration studyAcs B, Leung S, Pelekanou V, Bai Y, Martinez-Morilla S, Toki M, Chang M, Gholap A, Jadhav A, Hugh J, Bigras G, Laurinavicius A, Augulis R, Levenson R, Todd A, Piper T, Virk S, van der Vegt B, Hayes D, Dowsett M, Nielsen T, Rimm D. Abstract P4-02-01: Analytical validation of an automated digital scoring protocol for Ki67: International multicenter collaboration study. Cancer Research 2019, 79: p4-02-01-p4-02-01. DOI: 10.1158/1538-7445.sabcs18-p4-02-01.
• Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementJohnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB, Xu Y, Sosman JA, Davis RS, Balko JM. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight 2018, 3: e120360. PMID: 30568030, PMCID: PMC6338319, DOI: 10.1172/jci.insight.120360.
• CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancersPelekanou V, Villarroel-Espindola F, Schalper KA, Pusztai L, Rimm DL. CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers. Breast Cancer Research 2018, 20: 154. PMID: 30558648, PMCID: PMC6298021, DOI: 10.1186/s13058-018-1076-x.
• Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancerAltan M, Kidwell KM, Pelekanou V, Carvajal-Hausdorf DE, Schalper KA, Toki MI, Thomas DG, Sabel MS, Hayes DF, Rimm DL. Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. Npj Breast Cancer 2018, 4: 40. PMID: 30564631, PMCID: PMC6288133, DOI: 10.1038/s41523-018-0095-1.
• Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic MelanomaJohnson DB, Bordeaux J, Kim J, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle J, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research 2018, 24: 5250-5260. PMID: 30021908, PMCID: PMC6214750, DOI: 10.1158/1078-0432.ccr-18-0309.
• Immunological differences between primary and metastatic breast cancerSzekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. Immunological differences between primary and metastatic breast cancer. Annals Of Oncology 2018, 29: 2232-2239. PMID: 30203045, DOI: 10.1093/annonc/mdy399.
• Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinomaHartman DJ, Ahmad F, Ferris R, Rimm D, Pantanowitz L. Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncology 2018, 86: 278-287. PMID: 30409313, PMCID: PMC6260977, DOI: 10.1016/j.oraloncology.2018.10.005.
• correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialShi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals Of Oncology 2018, 29: 2152. PMID: 29701764, PMCID: PMC6225898, DOI: 10.1093/annonc/mdx805.
• P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLCAltan M, Toki M, Carvajal-Hausdorf D, Gettinger S, Herbst R, Rimm D. P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC. Journal Of Thoracic Oncology 2018, 13: s738. DOI: 10.1016/j.jtho.2018.08.1244.
• Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC MutationsToki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Journal Of Thoracic Oncology 2018, 13: 1884-1896. PMID: 30267840, PMCID: PMC6251746, DOI: 10.1016/j.jtho.2018.09.012.
• Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator studyAcs B, Pelekanou V, Bai Y, Martinez-Morilla S, Toki M, Leung SCY, Nielsen TO, Rimm DL. Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. Laboratory Investigation 2018, 99: 107-117. PMID: 30181553, DOI: 10.1038/s41374-018-0123-7.
• Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimensRawat RR, Ruderman D, Macklin P, Rimm DL, Agus DB. Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens. Npj Breast Cancer 2018, 4: 32. PMID: 30211313, PMCID: PMC6123433, DOI: 10.1038/s41523-018-0084-4.
• Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancerHastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick M, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, Montuenga L, Lifton R, Ferrone S, Kavathas P, Rimm D, Kaech S, Schalper K, Herbst R, Politi K. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer. Cancer Immunology Research 2018, 6: a09-a09. DOI: 10.1158/2326-6074.tumimm17-a09.
• An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancerRimm DL, Leung SCY, McShane LM, Bai Y, Bane AL, Bartlett JMS, Bayani J, Chang MC, Dean M, Denkert C, Enwere EK, Galderisi C, Gholap A, Hugh JC, Jadhav A, Kornaga EN, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes DF, Nielsen TO, Dowsett M. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Modern Pathology 2018, 32: 59-69. PMID: 30143750, DOI: 10.1038/s41379-018-0109-4.
• A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockersGettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nature Communications 2018, 9: 3196. PMID: 30097571, PMCID: PMC6086912, DOI: 10.1038/s41467-018-05032-8.
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal For ImmunoTherapy Of Cancer 2018, 6: 75. PMID: 30012210, PMCID: PMC6048854, DOI: 10.1186/s40425-018-0382-2.
• Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic RearrangementBellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner E, Schwartz PE, Santin AD. Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clinical Cancer Research 2018, 24: 3282-3291. PMID: 29351920, PMCID: PMC6050068, DOI: 10.1158/1078-0432.ccr-17-1805.
• Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learningKlauschen F, Müller K, Binder A, Bockmayr M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, Michiels S, Nielsen TO, Adams S, Savas P, Symmans F, Willis S, Gruosso T, Park M, Haibe-Kains B, Gallas B, Thompson AM, Cree I, Sotiriou C, Solinas C, Preusser M, Hewitt SM, Rimm D, Viale G, Loi S, Loibl S, Salgado R, Denkert C, Group O. Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Seminars In Cancer Biology 2018, 52: 151-157. PMID: 29990622, DOI: 10.1016/j.semcancer.2018.07.001.
• Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumorsMorgado M, Datar I, Wang J, Sanmamed M, McEachern K, Jenkins D, Chen L, Carvajal-Hausdorf D, Rimm D, Herbst R, Schalper K. Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors. Cancer Research 2018, 78: 1681-1681. DOI: 10.1158/1538-7445.am2018-1681.
• Abstract 3638: Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanomaWong P, Smithy J, Blenman K, Kluger H, Rimm D. Abstract 3638: Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. Cancer Research 2018, 78: 3638-3638. DOI: 10.1158/1538-7445.am2018-3638.
• Abstract 3621: High-plex immune marker spatial profiling quantitation by NanoString Digital Spatial Profiling technology and quantitative immunofluorescenceToki M, Wong P, Kluger H, Liu Y, Merritt C, Ong G, Warren S, Beechem J, Rimm D. Abstract 3621: High-plex immune marker spatial profiling quantitation by NanoString Digital Spatial Profiling technology and quantitative immunofluorescence. Cancer Research 2018, 78: 3621-3621. DOI: 10.1158/1538-7445.am2018-3621.
• Abstract 1695: A multi-institutional study to evaluate automated scoring of immunohistochemistry slides for assessment of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancerTaylor C, Jadhav A, Gholap A, Kamble G, Huang J, Gown A, Doshi I, Rimm D. Abstract 1695: A multi-institutional study to evaluate automated scoring of immunohistochemistry slides for assessment of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Cancer Research 2018, 78: 1695-1695. DOI: 10.1158/1538-7445.am2018-1695.
• Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancersLu C, Romo-Bucheli D, Wang X, Janowczyk A, Ganesan S, Gilmore H, Rimm D, Madabhushi A. Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers. Laboratory Investigation 2018, 98: 1438-1448. PMID: 29959421, PMCID: PMC6214731, DOI: 10.1038/s41374-018-0095-7.
• Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS TestingKim AS, Bartley AN, Bridge JA, Kamel-Reid S, Lazar AJ, Lindeman NI, Long TA, Merker JD, Rai AJ, Rimm DL, Rothberg PG, Vasalos P, Moncur JT. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing. JAMA Oncology 2018, 4: 838-841. PMID: 29242895, PMCID: PMC6145687, DOI: 10.1001/jamaoncol.2017.4021.
• Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancerGupta S, Mani NR, Carvajal-Hausdorf DE, Bossuyt V, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm DL. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Laboratory Investigation 2018, 98: 1076-1083. PMID: 29858579, PMCID: PMC6119113, DOI: 10.1038/s41374-018-0064-1.
• Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trialPelekanou V, Barlow WE, Nahleh Z, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L. Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial. Molecular Cancer Therapeutics 2018, 17: molcanther.1005.2017. PMID: 29588392, PMCID: PMC6548451, DOI: 10.1158/1535-7163.mct-17-1005.
• Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).Henick B, Datar I, Villarroel-Espindola F, Sanmamed M, Yu J, Tuktamyshov R, Li A, Toki M, Syrigos K, Rimm D, Chen L, Herbst R, Schalper K. Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC). Journal Of Clinical Oncology 2018, 36: 12002-12002. DOI: 10.1200/jco.2018.36.15_suppl.12002.
• The effect of black cohosh on Ki67 levels in DCIS patients.Hofstatter E, Trant A, Stavris K, Horowitz N, Killelea B, Lannin D, Neumeister V, Rimm D, Chagpar A. The effect of black cohosh on Ki67 levels in DCIS patients. Journal Of Clinical Oncology 2018, 36: e13541-e13541. DOI: 10.1200/jco.2018.36.15_suppl.e13541.
• Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).Datar I, Villarroel-Espindola F, Henick B, Syrigos K, Toki M, Rimm D, Ferrone S, Herbst R, Schalper K. Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2018, 36: 12015-12015. DOI: 10.1200/jco.2018.36.15_suppl.12015.
• Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter?Khunger M, Bordeaux J, Dakappagari N, Vaupel C, Khunger A, Hu B, Schalper K, Rimm D, Velcheti V. Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter? Journal Of Clinical Oncology 2018, 36: 12058-12058. DOI: 10.1200/jco.2018.36.15_suppl.12058.
• PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).Bordeaux J, Dakappagari N, Pennell N, Stevenson J, Khunger M, Vaupel C, Schalper K, Rimm D, Velcheti V. PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC). Journal Of Clinical Oncology 2018, 36: 12059-12059. DOI: 10.1200/jco.2018.36.15_suppl.12059.
• Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).Luen S, Salgado R, Dieci M, Vingiani A, Curigliano G, Hubbard R, Castaneda Altamirano C, Sanchez J, D'Alfonso T, Cheng E, Castillo Garcia M, Adams S, Ahmed F, Rimm D, Demaria S, Symmans W, Michiels S, Loi S. Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC). Journal Of Clinical Oncology 2018, 36: 571-571. DOI: 10.1200/jco.2018.36.15_suppl.571.
• Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upKadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals Of Oncology 2018, 29: 1072. PMID: 29688333, PMCID: PMC6887935, DOI: 10.1093/annonc/mdx062.
• Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung CancerGettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst R. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer. Journal Of Thoracic Oncology 2018, 13: 831-839. PMID: 29578107, PMCID: PMC6485248, DOI: 10.1016/j.jtho.2018.03.008.
• An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patientsMoore LM, Wilkinson R, Altan M, Toki M, Carvajal-Hausdorf DE, McGuire J, Ehrlich BE, Rimm DL. An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients. Npj Breast Cancer 2018, 4: 6. PMID: 29560416, PMCID: PMC5847580, DOI: 10.1038/s41523-018-0057-7.
• Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneityCorrea BRS, Hu J, Penalva LOF, Schlegel R, Rimm DL, Galante PAF, Agarwal S. Patient-derived conditionally reprogrammed cells maintain intra-tumor genetic heterogeneity. Scientific Reports 2018, 8: 4097. PMID: 29511269, PMCID: PMC5840339, DOI: 10.1038/s41598-018-22427-1.
• Not Just Digital Pathology, Intelligent Digital PathologyAcs B, Rimm DL. Not Just Digital Pathology, Intelligent Digital Pathology. JAMA Oncology 2018, 4: 403-404. PMID: 29392271, DOI: 10.1001/jamaoncol.2017.5449.
• Abstract P2-09-06: Quantitative spatial profiling of tumor associated macrophages and the PD-1/PD-L1 interaction in breast cancerPelekanou V, Neumeister V, Pusztai L, Rimm D. Abstract P2-09-06: Quantitative spatial profiling of tumor associated macrophages and the PD-1/PD-L1 interaction in breast cancer. Cancer Research 2018, 78: p2-09-06-p2-09-06. DOI: 10.1158/1538-7445.sabcs17-p2-09-06.
• Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancerRimm D, Carvajal-Hausdorf D, Harbeck N, Fumagalli D, Rodrik-Outmezguine V, delaPena L, deAzambuja E, Huober J, Baselga J, Piccart M, Holmes E, Pusztai L. Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer. Cancer Research 2018, 78: p2-09-07-p2-09-07. DOI: 10.1158/1538-7445.sabcs17-p2-09-07.
• Abstract P2-09-18: Multiplexed (18-Plex) measurement of protein targets in trastuzumab-treated patients using imaging mass cytometryCarvajal-Hausdorf D, Stanton K, Patsenker J, Villarroel-Espindola F, Esch A, Montgomery R, Psyrri A, Kalogeras K, Kotoula V, Fountzilas G, Schalper K, Kluger Y, Rimm D. Abstract P2-09-18: Multiplexed (18-Plex) measurement of protein targets in trastuzumab-treated patients using imaging mass cytometry. Cancer Research 2018, 78: p2-09-18-p2-09-18. DOI: 10.1158/1538-7445.sabcs17-p2-09-18.
• Abstract P1-08-02: Breast tumor-specific MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through MHC-II receptor checkpoint engagementBalko J, Johnson D, Ericsson-Gonzalez P, Nixon M, Salgado R, Sanchez V, Shreeder D, Rimm D, Loi S, Kim J, Bordeaux J, Sanders M, Davis R. Abstract P1-08-02: Breast tumor-specific MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through MHC-II receptor checkpoint engagement. Cancer Research 2018, 78: p1-08-02-p1-08-02. DOI: 10.1158/1538-7445.sabcs17-p1-08-02.
• Abstract P2-03-02: Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancerGupta S, Carvajal-Hausdorf D, Wasserman B, Ho K, Weidler J, Wong W, Rhees B, Bates M, Rimm D. Abstract P2-03-02: Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Cancer Research 2018, 78: p2-03-02-p2-03-02. DOI: 10.1158/1538-7445.sabcs17-p2-03-02.
• Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trialCampbell M, Yau C, Borowsky A, Vandenberg S, Wolf D, Rimm D, Nanda R, Liu M, Brown-Swigart L, Hirst G, Asare S, van't Veer L, Yee D, DeMichele A, Berry D, Esserman L. Abstract PD6-08: Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial. Cancer Research 2018, 78: pd6-08-pd6-08. DOI: 10.1158/1538-7445.sabcs17-pd6-08.
• Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung CancerGettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discovery 2017, 7: cd-17-0593. PMID: 29025772, PMCID: PMC5718941, DOI: 10.1158/2159-8290.cd-17-0593.
• Implications of the tumor immune microenvironment for staging and therapeuticsTaube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology 2017, 31: 214-234. PMID: 29192647, PMCID: PMC6132263, DOI: 10.1038/modpathol.2017.156.
• Worldwide Frequency of Commonly Detected EGFR MutationsGraham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, Rimm DL. Worldwide Frequency of Commonly Detected EGFR Mutations. Archives Of Pathology & Laboratory Medicine 2017, 142: 163-167. PMID: 29106293, DOI: 10.5858/arpa.2016-0579-cp.
• Assessing Tumor-Infiltrating Lymphocytes in Solid TumorsHendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors. Advances In Anatomic Pathology 2017, 24: 311-335. PMID: 28777143, PMCID: PMC5638696, DOI: 10.1097/pap.0000000000000161.
• MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung CancerVelcheti V, Bordeaux J, Dakappagari N, Pennell N, Stevenson J, Khunger M, Kim J, Schalper K, Rimm D. MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s1852. DOI: 10.1016/j.jtho.2017.09.562.
• PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung CancerWang X, Corredor G, Romero E, Schalper K, Yang M, Rimm D, Velcheti V, Madabhushi A. PUB024 Clusters Spatial Arrangement of Tumor Infiltrating Lymphocyte and Cancer Nuclei Predicts Recurrence in Early Stage Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s2372-s2373. DOI: 10.1016/j.jtho.2017.09.1887.
• Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancerCarvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. Journal For ImmunoTherapy Of Cancer 2017, 5: 81. PMID: 29037255, PMCID: PMC5644103, DOI: 10.1186/s40425-017-0285-7.
• Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerDieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D’Alfonso T, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R, Cancer O. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars In Cancer Biology 2017, 52: 16-25. PMID: 29024776, DOI: 10.1016/j.semcancer.2017.10.003.
• Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significancePelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL. Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Research 2017, 19: 109. PMID: 28946899, PMCID: PMC5613519, DOI: 10.1186/s13058-017-0898-2.
• High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescenceWasserman BE, Carvajal-Hausdorf DE, Ho K, Wong W, Wu N, Chu VC, Lai EW, Weidler JM, Bates M, Neumeister V, Rimm DL. High concordance of a closed-system, RT-qPCR breast cancer assay for HER2 mRNA, compared to clinically determined immunohistochemistry, fluorescence in situ hybridization, and quantitative immunofluorescence. Laboratory Investigation 2017, 97: 1521-1526. PMID: 28892092, PMCID: PMC5711560, DOI: 10.1038/labinvest.2017.93.
• Assessing Tumor-infiltrating Lymphocytes in Solid TumorsHendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors. Advances In Anatomic Pathology 2017, 24: 235-251. PMID: 28777142, PMCID: PMC5564448, DOI: 10.1097/pap.0000000000000162.
• B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating LymphocytesAltan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Clinical Cancer Research 2017, 23: 5202-5209. PMID: 28539467, PMCID: PMC5581684, DOI: 10.1158/1078-0432.ccr-16-3107.
• Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significancePelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Research 2017, 19: 91. PMID: 28784153, PMCID: PMC5547502, DOI: 10.1186/s13058-017-0884-8.
• PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint InhibitorsKluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research 2017, 23: 4270-4279. PMID: 28223273, PMCID: PMC5540774, DOI: 10.1158/1078-0432.ccr-16-3146.
• A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung CancerRimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer. JAMA Oncology 2017, 3: 1051-1058. PMID: 28278348, PMCID: PMC5650234, DOI: 10.1001/jamaoncol.2017.0013.
• ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCCAlvarado D, Ligon GF, Lillquist JS, Seibel SB, Wallweber G, Neumeister VM, Rimm DL, McMahon G, LaVallee TM. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC. PLOS ONE 2017, 12: e0181356. PMID: 28723928, PMCID: PMC5517012, DOI: 10.1371/journal.pone.0181356.
• Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient SurvivalMoore LM, England A, Ehrlich BE, Rimm DL. Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival. Molecular Cancer Research 2017, 15: 942-952. PMID: 28275088, PMCID: PMC5500411, DOI: 10.1158/1541-7786.mcr-16-0408.
• Abstract 3810: Validation of novel high-plex protein spatial profiling quantitation based on NanoString's Digital Spatial Profiling (DSP) technology with quantitative fluorescence (QIF)Toki M, Merritt C, Ong G, Beechem J, Carvajal-Hausdorf D, Bai Y, Rimm D. Abstract 3810: Validation of novel high-plex protein spatial profiling quantitation based on NanoString's Digital Spatial Profiling (DSP) technology with quantitative fluorescence (QIF). Cancer Research 2017, 77: 3810-3810. DOI: 10.1158/1538-7445.am2017-3810.
• Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometryVillarroel-Espindola F, Carvajal-Hausdorf D, Datar I, Esch A, Rashidi N, Nassar A, Ren S, Montgomery R, Herbst R, Rimm D, Schalper K. Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometry. Cancer Research 2017, 77: 1635-1635. DOI: 10.1158/1538-7445.am2017-1635.
• Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC)Datar I, Wang J, Mani N, Villarroel-Espindola F, Ryan P, Sanmamed M, McEachern K, Jenkins D, Rimm D, Chen L, Herbst R, Schalper K. Abstract 5600: Simultaneous measurement and clinical significance of PD-1, LAG-3 and TIM-3 in non-small cell lung cancer (NSCLC). Cancer Research 2017, 77: 5600-5600. DOI: 10.1158/1538-7445.am2017-5600.
• Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC)Villarroel-Espindola F, Datar I, Velcheti V, Rimm D, Herbst R, Schalper K. Abstract 5657: Objective measurement and significance of VISTA (PD-1H) expression in non-small cell lung cancer (NSCLC). Cancer Research 2017, 77: 5657-5657. DOI: 10.1158/1538-7445.am2017-5657.
• Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations.Toki M, Mani N, Smithy J, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Syrigos K, Rimm D. Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations. Journal Of Clinical Oncology 2017, 35: 9076-9076. DOI: 10.1200/jco.2017.35.15_suppl.9076.
• Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.Datar I, Mani N, Henick B, Wurtz A, Kaftan E, Herbst R, Rimm D, Gettinger S, Politi K, Schalper K. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal Of Clinical Oncology 2017, 35: e14611-e14611. DOI: 10.1200/jco.2017.35.15_suppl.e14611.
• Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial.Pelekanou V, Barlow W, von Wahlde M, Wasserman B, Lo Y, Hayes D, Hortobagyi G, Gralow J, Tripathy D, Livingston R, Porter P, Nahleh Z, Rimm D, Pusztai L. Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial. Journal Of Clinical Oncology 2017, 35: 519-519. DOI: 10.1200/jco.2017.35.15_suppl.519.
• Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).Johnson D, Bordeaux J, Kim J, Vaupel C, Rimm D, Ho T, Joseph R, Daud A, Conry R, Gaughan E, Dimou A, Balko J, Smithy J, Witte J, McKee S, Dominiak N, Dabbas B, Hall J, Dakappagari N. Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM). Journal Of Clinical Oncology 2017, 35: 9517-9517. DOI: 10.1200/jco.2017.35.15_suppl.9517.
• Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanomaSmithy JW, Moore LM, Pelekanou V, Rehman J, Gaule P, Wong PF, Neumeister VM, Sznol M, Kluger HM, Rimm DL. Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2017, 5: 25. PMID: 28331615, PMCID: PMC5359951, DOI: 10.1186/s40425-017-0229-2.
• Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancerRimm D, McShane L, Leung S, Bai Y, Bane A, Bartlett J, Bayani J, Chang M, Dean M, Denkert C, Enwere E, Galderisi C, Gholap A, Hugh J, Jadhav A, Kornaga E, Laurinavicius A, Levenson R, Lima J, Miller K, Pantanowitz L, Piper T, Ruan J, Srinivasan M, Virk S, Wu Y, Yang H, Hayes D, Nielsen T, Dowsett M. Abstract P1-03-01: An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer. Cancer Research 2017, 77: p1-03-01-p1-03-01. DOI: 10.1158/1538-7445.sabcs16-p1-03-01.
• Abstract P4-03-04: Tumor infiltrating macrophages, lymphocytes and matrix metalloproteinase 9 (MMP-9) expression in breast cancerPelekanou V, Brown J, Rimm D. Abstract P4-03-04: Tumor infiltrating macrophages, lymphocytes and matrix metalloproteinase 9 (MMP-9) expression in breast cancer. Cancer Research 2017, 77: p4-03-04-p4-03-04. DOI: 10.1158/1538-7445.sabcs16-p4-03-04.
• Abstract P6-10-02: MHC-II positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltratesBalko J, Loi S, Giltnane J, Combs S, Estrada M, Sanchez V, Rimm D, Sanders M, Salgado R, Gomez H, Johnson D. Abstract P6-10-02: MHC-II positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates. Cancer Research 2017, 77: p6-10-02-p6-10-02. DOI: 10.1158/1538-7445.sabcs16-p6-10-02.
• Abstract P1-03-07: High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescenceWasserman B, Carvajal-Hausdorf D, Ho K, Wong W, Wu N, Chu V, Lai E, Weidler J, Bates M, Neumenister V, Rimm D. Abstract P1-03-07: High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence. Cancer Research 2017, 77: p1-03-07-p1-03-07. DOI: 10.1158/1538-7445.sabcs16-p1-03-07.
• Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significanceCarvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecologic Oncology 2017, 145: 154-158. PMID: 28196634, PMCID: PMC5941302, DOI: 10.1016/j.ygyno.2017.02.002.
• A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology 2017, 3: 256-259. PMID: 27541827, PMCID: PMC5491359, DOI: 10.1001/jamaoncol.2016.3015.
• Proof of the quantitative potential of immunofluorescence by mass spectrometryToki MI, Cecchi F, Hembrough T, Syrigos KN, Rimm DL. Proof of the quantitative potential of immunofluorescence by mass spectrometry. Laboratory Investigation 2017, 97: 329-334. PMID: 28092364, PMCID: PMC5334147, DOI: 10.1038/labinvest.2016.148.
• Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerSchalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clinical Cancer Research 2017, 23: 370-378. PMID: 27440266, PMCID: PMC6350535, DOI: 10.1158/1078-0432.ccr-16-0150.
• Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialShi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Annals Of Oncology 2017, 28: 128-135. PMID: 28177460, PMCID: PMC5834036, DOI: 10.1093/annonc/mdw434.
• Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-upKadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals Of Oncology 2017, 28: 75-82. PMID: 27687306, PMCID: PMC5982809, DOI: 10.1093/annonc/mdw436.
• Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune functionChoi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals Of Oncology 2017, 28: 83-89. PMID: 28177435, PMCID: PMC6246501, DOI: 10.1093/annonc/mdw437.
• Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2017, 28: 75-82. PMID: 31792518, DOI: 10.1093/annonc/mdw436.
• MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC). Journal Of Thoracic Oncology 2017, 12: s430-s431. DOI: 10.1016/j.jtho.2016.11.501.
• P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT BiomarkersChoi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick M, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, Chiang A, Lifton R, Chen L, Herbst R, Politi K, Gettinger S. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT Biomarkers. Journal Of Thoracic Oncology 2017, 12: s1331-s1332. DOI: 10.1016/j.jtho.2016.11.1884.
• P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and BiomarkersRothberg B, Das R, Jackson L, Lazowski H, Bai Y, O'Neill D, Roberts S, Rothberg J, Herbst R, Kim A, Boffa D, Rimm D, Detterbeck F, Tanoue L. P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers. Journal Of Thoracic Oncology 2017, 12: s623-s624. DOI: 10.1016/j.jtho.2016.11.801.
• P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted TherapyAltan M, Pelekanou V, Schalper K, Toki M, Herbst R, Rimm D. P2.01-046 Quantitative Measurement of B7-H3 Protein Expression and Its Association with B7-H4, PD-L1 and TILs in NSCLC Topic: Immune Mechanisms in Thoracic Cancer and Targeted Therapy. Journal Of Thoracic Oncology 2017, 12: s813-s814. DOI: 10.1016/j.jtho.2016.11.1098.
• P3.02c-067 Validation of PD-L1 Expression on Circulating Tumor Cells in Lung Cancer Topic: IT BiomarkersPircher T, Rimm D, Arnold L, Singh V. P3.02c-067 Validation of PD-L1 Expression on Circulating Tumor Cells in Lung Cancer Topic: IT Biomarkers. Journal Of Thoracic Oncology 2017, 12: s1316-s1317. DOI: 10.1016/j.jtho.2016.11.1862.
• Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditionsGao B, Huang C, Kernstine K, Pelekanou V, Kluger Y, Jiang T, Peters-Hall JR, Coquelin M, Girard L, Zhang W, Huffman K, Oliver D, Kinose F, Haura E, Teer JK, Rix U, Le AT, Aisner DL, Varella-Garcia M, Doebele RC, Covington KR, Hampton OA, Doddapaneni HV, Jayaseelan JC, Hu J, Wheeler DA, Shay JW, Rimm DL, Gazdar A, Minna JD. Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 2016, 5: 11114-11126. PMID: 28052041, PMCID: PMC5355251, DOI: 10.18632/oncotarget.14366.
• Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancerRehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, McLaughlin J, Schalper KA, Rimm DL. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Modern Pathology 2016, 30: 340-349. PMID: 27834350, PMCID: PMC5334264, DOI: 10.1038/modpathol.2016.186.
• PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer: Topic: Pathology.Toki M, Cecchi F, Hembrough T, Syrigos K, Rimm D. PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer: Topic: Pathology. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S287. PMID: 27969497, DOI: 10.1016/j.jtho.2016.09.065.
• ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry: Topic: Pathology.Rimm D, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Hirsch F, Wistuba II. ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry: Topic: Pathology. Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer 2016, 11: S249. PMID: 27969440, DOI: 10.1016/j.jtho.2016.09.006.
• ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry Topic: PathologyRimm D, Han G, Taube J, Yi E, Bridge J, Flieder D, Homer R, West W, Wu H, Roden A, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Hirsch F, Wistuba I. ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry Topic: Pathology. Journal Of Thoracic Oncology 2016, 11: s249. DOI: 10.1016/j.jtho.2016.09.006.
• PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non–Small Cell Lung Cancer Topic: PathologyToki M, Cecchi F, Hembrough T, Syrigos K, Rimm D. PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non–Small Cell Lung Cancer Topic: Pathology. Journal Of Thoracic Oncology 2016, 11: s287. DOI: 10.1016/j.jtho.2016.09.065.
• Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.Choi M, Kadara H, Zhang J, Cuentas EP, Canales JR, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee JJ, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2016 PMID: 27687303, DOI: 10.1093/annonc/mdw437.
• A proposal for validation of antibodiesUhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, Yamamoto T. A proposal for validation of antibodies. Nature Methods 2016, 13: 823-827. PMID: 27595404, PMCID: PMC10335836, DOI: 10.1038/nmeth.3995.
• Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancerMani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Research 2016, 18: 78. PMID: 27473061, PMCID: PMC4966732, DOI: 10.1186/s13058-016-0737-x.
• EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung AdenocarcinomaToki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. Journal Of Thoracic Oncology 2016, 11: 1901-1911. PMID: 27449805, PMCID: PMC5075503, DOI: 10.1016/j.jtho.2016.06.025.
• Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinomaChoi M, Kadara H, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee J, Lifton R, Herbst R, Wistuba I. Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma. Cancer Research 2016, 76: 142-142. DOI: 10.1158/1538-7445.am2016-142.
• Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinomaKadara H, Choi M, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee J, Lifton R, Wistuba I, Herbst R. Abstract 89: Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma. Cancer Research 2016, 76: 89-89. DOI: 10.1158/1538-7445.am2016-89.
• Abstract 1196: Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHNLigon G, Lillquist J, Seibel S, Wallweber J, Neumeister V, Rimm D, LaVallee T, Alvarado D. Abstract 1196: Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN. Cancer Research 2016, 76: 1196-1196. DOI: 10.1158/1538-7445.am2016-1196.
• [Letter to the Editor] The need for improved education and training in research antibody usage and validation practicesFreedman LP, Gibson MC, Bradbury AR, Buchberg AM, Davis D, Dolled-Filhart MP, Lund-Johansen F, Rimm DL. [Letter to the Editor] The need for improved education and training in research antibody usage and validation practices. BioTechniques 2016, 61: 16-18. PMID: 27401669, DOI: 10.2144/000114431.
• Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working groupDenkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology 2016, 29: 1155-1164. PMID: 27363491, DOI: 10.1038/modpathol.2016.109.
• Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoCocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. British Journal Of Cancer 2016, 115: 303-311. PMID: 27351214, PMCID: PMC4973158, DOI: 10.1038/bjc.2016.198.
• Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurementZarrella ER, Coulter M, Welsh AW, Carvajal DE, Schalper KA, Harigopal M, Rimm D, Neumeister V. Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement. Laboratory Investigation 2016, 96: 1016-1025. PMID: 27348626, PMCID: PMC5008858, DOI: 10.1038/labinvest.2016.73.
• Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer CellsForloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V, Toki M, Wurtz A, Melnick MA, Kobayashi S, Homer RJ, Rimm DL, Gettinger SJ, Politi K, Dogra SK, Wajapeyee N. Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells. Cell Reports 2016, 16: 457-471. PMID: 27346347, PMCID: PMC4945411, DOI: 10.1016/j.celrep.2016.05.087.
• Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC).Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Chiang A, Velcheti V, Kaftan E, Zhang J, Lu L, Rimm D, Han B, Lu H, Zhao H, Herbst R. Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal Of Clinical Oncology 2016, 34: 8566-8566. DOI: 10.1200/jco.2016.34.15_suppl.8566.
• Association between DNA level aberrations and immune cell infiltration in breast cancer.Safonov A, Jiang T, Bianchini G, Platt J, Shi W, Rimm D, Pusztai L, Hatzis C. Association between DNA level aberrations and immune cell infiltration in breast cancer. Journal Of Clinical Oncology 2016, 34: 3078-3078. DOI: 10.1200/jco.2016.34.15_suppl.3078.
• Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC).Schalper K, Mani N, Toki M, Carvajal-Hausdorf D, Herbst R, Rimm D. Clinical value of measuring T-cell activation and proliferation using multiplexed quantitative fluorescence in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 11610-11610. DOI: 10.1200/jco.2016.34.15_suppl.11610.
• Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.Gaule P, Rehman J, Smithy J, Toki M, Han G, Neumeister V, Carvajal-Hausdorf D, Schalper K, Pelekanou V, Wasserman B, Herbst R, Rimm D. Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer. Journal Of Clinical Oncology 2016, 34: 9040-9040. DOI: 10.1200/jco.2016.34.15_suppl.9040.
• PD-L1 Expression in Lung CancerYu H, Boyle TA, Zhou C, Rimm D, Hirsch FR. PD-L1 Expression in Lung Cancer. Journal Of Thoracic Oncology 2016, 11: 964-975. PMID: 27117833, PMCID: PMC5353357, DOI: 10.1016/j.jtho.2016.04.014.
• Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceBalko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine 2016, 8: 334ra53. PMID: 27075627, PMCID: PMC5256931, DOI: 10.1126/scitranslmed.aad3001.
• RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsLoi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research 2016, 22: 1499-1509. PMID: 26515496, PMCID: PMC4794351, DOI: 10.1158/1078-0432.ccr-15-1125.
• Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarkerMani N, Schalper K, Hatzis C, Chagpar A, Pusztai L, Rimm D. Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker. Cancer Research 2016, 76: p5-07-09-p5-07-09. DOI: 10.1158/1538-7445.sabcs15-p5-07-09.
• Abstract S5-01: Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapiesPusztai L, Shi W, Jiang T, Nuciforo P, Holmes E, Harbeck N, Sotiriou C, Rimm D, Hatzis C, de la Peña L, Armour A, Piccart-Gebhart M, Baselga J. Abstract S5-01: Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies. Cancer Research 2016, 76: s5-01-s5-01. DOI: 10.1158/1538-7445.sabcs15-s5-01.
• Abstract P3-07-06: Objective measurement of HER2 (ERBB2) intracellular and extracellular domain spatial co-localization stratifies benefit from adjuvant trastuzumabCarvajal-Hausdorf D, Toki M, Schalper K, Pusztai L, Psyrri A, Kalogeras K, Kotoula V, Fountzilas G, Rimm D. Abstract P3-07-06: Objective measurement of HER2 (ERBB2) intracellular and extracellular domain spatial co-localization stratifies benefit from adjuvant trastuzumab. Cancer Research 2016, 76: p3-07-06-p3-07-06. DOI: 10.1158/1538-7445.sabcs15-p3-07-06.
• Abstract P4-09-22: Quantitative immuno-fluorescent evaluation of Her2 expression levels in a prospectively collected cohort of breast cancer cases: Comparison to conventional IHC scoring and FISHNeumeister V, Yan S, McGuire J, Carvajal D, Prasad M, Rimm D. Abstract P4-09-22: Quantitative immuno-fluorescent evaluation of Her2 expression levels in a prospectively collected cohort of breast cancer cases: Comparison to conventional IHC scoring and FISH. Cancer Research 2016, 76: p4-09-22-p4-09-22. DOI: 10.1158/1538-7445.sabcs15-p4-09-22.
• Abstract P5-07-12: Local nuclear architecture features from H&E images predict early versus distant recurrence in lymph node negative, ER+ breast cancersAli S, Rimm D, Ganesan S, Madabhushi A. Abstract P5-07-12: Local nuclear architecture features from H&E images predict early versus distant recurrence in lymph node negative, ER+ breast cancers. Cancer Research 2016, 76: p5-07-12-p5-07-12. DOI: 10.1158/1538-7445.sabcs15-p5-07-12.
• miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast CancerAdams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Research 2016, 76: 927-939. PMID: 26676753, PMCID: PMC4755913, DOI: 10.1158/0008-5472.can-15-2321.
• Early and multiple origins of metastatic lineages within primary tumorsZhao ZM, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL, Townsend JP. Early and multiple origins of metastatic lineages within primary tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2140-2145. PMID: 26858460, PMCID: PMC4776530, DOI: 10.1073/pnas.1525677113.
• Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell CarcinomaVassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Clinical Cancer Research 2016, 22: 704-713. PMID: 26408403, DOI: 10.1158/1078-0432.ccr-15-1543.
• Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaWilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical Cancer Research 2016, 22: 374-382. PMID: 26307133, PMCID: PMC4821426, DOI: 10.1158/1078-0432.ccr-15-1162.
• Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerMcLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelakanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer. JAMA Oncology 2016, 2: 1-9. PMID: 26562159, PMCID: PMC4941982, DOI: 10.1001/jamaoncol.2015.3638.
• Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical TrialBartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW. Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives Of Pathology & Laboratory Medicine 2016, 140: 66-74. PMID: 26717057, DOI: 10.5858/arpa.2014-0599-oa.
• Loss of antigenicity with tissue age in breast cancerCombs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL. Loss of antigenicity with tissue age in breast cancer. Laboratory Investigation 2015, 96: 264-269. PMID: 26568292, DOI: 10.1038/labinvest.2015.138.
• GENO-21BRCA1 PROTEIN EXPRESSION PREDICTS SURVIVAL IN GLIOBLASTOMA PATIENTS FROM A NRG ONCOLOGY/RTOG COHORTVassilakopoulou M, Won M, Curran W, Souhami L, Prados M, Langer C, Rimm D, Hanna J, Neumeister V, Smart W, Diaz A, Atkins J, Komarnicky L, Schultz C, Howard S, Dicker A, Knisely J. GENO-21BRCA1 PROTEIN EXPRESSION PREDICTS SURVIVAL IN GLIOBLASTOMA PATIENTS FROM A NRG ONCOLOGY/RTOG COHORT. Neuro-Oncology 2015, 17: v96-v96. PMCID: PMC4638813, DOI: 10.1093/neuonc/nov215.21.
• Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancerSchalper K, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Chen L, Sanmamed M, Herbst R, Rimm D. Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer. Journal For ImmunoTherapy Of Cancer 2015, 3: p415. PMCID: PMC4652522, DOI: 10.1186/2051-1426-3-s2-p415.
• Dissecting the tumor micro-environment in triple negative breast cancer identifies a mutually exclusive expression pattern of the immune co-inhibitory molecules B7-H4 and PD-L1Shaffer D, Cortez-Retamozo V, Nagashima K, Zi T, Shu C, Feldman I, Neumeister V, Smith J, Zafari M, Larson R, Silver M, Mabry R, Briskin M, Novobrantseva T, Rimm D, Sathyanarayanan S. Dissecting the tumor micro-environment in triple negative breast cancer identifies a mutually exclusive expression pattern of the immune co-inhibitory molecules B7-H4 and PD-L1. Journal For ImmunoTherapy Of Cancer 2015, 3: o17. PMCID: PMC4645464, DOI: 10.1186/2051-1426-3-s2-o17.
• BRCA1 Protein Expression Predicts Survival in Glioblastoma Multiforme (GBM) Patients From a RTOG CohortVassilakopoulou M, Won M, Curran W, Souhami L, Prados M, Langer C, Rimm D, Hanna J, Neumeister V, Melian E, Diaz A, Atkins J, Brady L, Schultz C, Howard S, Dicker A, Knisely J. BRCA1 Protein Expression Predicts Survival in Glioblastoma Multiforme (GBM) Patients From a RTOG Cohort. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s141. DOI: 10.1016/j.ijrobp.2015.07.335.
• Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC)McLaughlin J, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Velcheti V, Haack H, Silver M, Herbst R, LoRusso P, Rimm D. Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC). 2015, 1310-1310. DOI: 10.1158/1538-7445.am2015-1310.
• Abstract LB-300: Reintroduction of tumor-suppressor miR-34a shows therapeutic efficacy in triple-negative breast cancerAdams B, Wali V, Cheng C, Inukai S, Rimm D, Pusztai L, Saltzman M, Slack F. Abstract LB-300: Reintroduction of tumor-suppressor miR-34a shows therapeutic efficacy in triple-negative breast cancer. 2015, lb-300-lb-300. DOI: 10.1158/1538-7445.am2015-lb-300.
• Abstract 2347: Multiplexed quantitative assessment and prognostic value of TIL subtypes in non-small cell lung cancerSchalper K, Hoyt C, Wang C, Rimm D. Abstract 2347: Multiplexed quantitative assessment and prognostic value of TIL subtypes in non-small cell lung cancer. 2015, 2347-2347. DOI: 10.1158/1538-7445.am2015-2347.
• Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic SitesKluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research 2015, 21: 3052-3060. PMID: 25788491, PMCID: PMC4490112, DOI: 10.1158/1078-0432.ccr-14-3073.
• Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate CancerBlume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research 2015, 21: 2591-2600. PMID: 25733599, DOI: 10.1158/1078-0432.ccr-14-2603.
• Correlation of miR200a expression with survival in patients with small, lymph node negative head and neck squamous cell carcinoma.Vasilakopoulou M, Hanna J, Rampias T, Perisanidis C, Rimm D, Psyrri A. Correlation of miR200a expression with survival in patients with small, lymph node negative head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2015, 33: e17062-e17062. DOI: 10.1200/jco.2015.33.15_suppl.e17062.
• The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers.Hurwitz M, Adeniran A, Yao X, Hafez N, Schalper K, Rimm D, Petrylak D. The effect of BCG intravesical therapy and recurrence on PDL1 expression in non-invasive bladder cancers. Journal Of Clinical Oncology 2015, 33: e15504-e15504. DOI: 10.1200/jco.2015.33.15_suppl.e15504.
• Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer.Schalper K, Carvajal-Hausdorf D, McLaughlin J, Altan M, Syrigos K, Herbst R, Rimm D. Significance of PD-L1, IDO-1, and B7-H4 expression in lung cancer. Journal Of Clinical Oncology 2015, 33: 3067-3067. DOI: 10.1200/jco.2015.33.15_suppl.3067.
• Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer.Altan M, Schalper K, Silver M, Rimm D. Expression and significance of the co-regulatory ligands B7-H4 and PD-L1 in triple negative breast cancer. Journal Of Clinical Oncology 2015, 33: 1087-1087. DOI: 10.1200/jco.2015.33.15_suppl.1087.
• Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast CancerCarvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer. Journal Of The National Cancer Institute 2015, 107 PMID: 25991002, PMCID: PMC4554192, DOI: 10.1093/jnci/djv136.
• High level PHGDH expression in breast is predominantly associated with keratin 5‐positive cell lineage independently of malignancyGromova I, Gromov P, Honma N, Kumar S, Rimm D, Talman ML, Wielenga VT, Moreira JM. High level PHGDH expression in breast is predominantly associated with keratin 5‐positive cell lineage independently of malignancy. Molecular Oncology 2015, 9: 1636-1654. PMID: 26026368, PMCID: PMC5528790, DOI: 10.1016/j.molonc.2015.05.003.
• PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain MetastasisJilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM. PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clinical Cancer Research 2015, 21: 2138-2147. PMID: 25316811, PMCID: PMC4397107, DOI: 10.1158/1078-0432.ccr-14-0861.
• Abstract P3-06-26: Measurement of domain-specific HER2 (ERBB2) expression classifies benefit from Trastuzumab in breast cancerCarvajal-Hausdorf D, Schalper K, Pusztai L, Psyrri A, Kalogeras K, Kotoula V, Fountzilas G, Rimm D. Abstract P3-06-26: Measurement of domain-specific HER2 (ERBB2) expression classifies benefit from Trastuzumab in breast cancer. 2015, p3-06-26-p3-06-26. DOI: 10.1158/1538-7445.sabcs14-p3-06-26.
• Abstract P4-07-12: Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancerAdams B, Pusztai L, Rimm D, Slack F. Abstract P4-07-12: Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancer. 2015, p4-07-12-p4-07-12. DOI: 10.1158/1538-7445.sabcs14-p4-07-12.
• Abstract S1-08: Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survivalBalko J, Denkert C, Salgado R, O'Hely M, Savas P, Beavis P, Darcy P, Combs S, Rimm D, Giltnane J, Estrada M, Sanders M, Cook R, Wang K, Miller V, Stephens P, Yelensky R, Pinto J, Doimi F, Gomez H, Arteaga C, Loi S. Abstract S1-08: Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival. 2015, s1-08-s1-08. DOI: 10.1158/1538-7445.sabcs14-s1-08.
• PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast CancerWimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunology Research 2015, 3: 326-332. PMID: 25527356, PMCID: PMC4390454, DOI: 10.1158/2326-6066.cir-14-0133.
• Expertise vs Evidence in Assessment of Breast Biopsies: An Atypical ScienceDavidson NE, Rimm DL. Expertise vs Evidence in Assessment of Breast Biopsies: An Atypical Science. JAMA 2015, 313: 1109-1110. PMID: 25781438, DOI: 10.1001/jama.2015.1945.
• Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing ChemotherapiesJeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, Jiang T, Rimm DL, Cardiff RD, Mills GB, Smith JW, Osterman AL, Kluger Y, Ronai Z. Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies. Cancer Cell 2015, 27: 354-369. PMID: 25759021, PMCID: PMC4356903, DOI: 10.1016/j.ccell.2015.02.006.
• Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung CancerSchalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer. Journal Of The National Cancer Institute 2015, 107 PMID: 25650315, PMCID: PMC4565530, DOI: 10.1093/jnci/dju435.
• Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencingKunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, Höög A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Human Molecular Genetics 2015, 24: 2318-2329. PMID: 25576899, PMCID: PMC4380073, DOI: 10.1093/hmg/ddu749.
• Quantitative measurement of cancer tissue biomarkers in the lab and in the clinicCarvajal-Hausdorf D, Schalper KA, Neumeister V, Rimm DL. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Laboratory Investigation 2014, 95: 385-396. PMID: 25502176, PMCID: PMC4383674, DOI: 10.1038/labinvest.2014.157.
• Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical CarcinomaJuhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T. Whole-Exome Sequencing Characterizes the Landscape of Somatic Mutations and Copy Number Alterations in Adrenocortical Carcinoma. The Journal Of Clinical Endocrinology & Metabolism 2014, 100: e493-e502. PMID: 25490274, PMCID: PMC5393505, DOI: 10.1210/jc.2014-3282.
• Quantitative assessment of miR34a as an independent prognostic marker in breast cancerAgarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. British Journal Of Cancer 2014, 112: 61-68. PMID: 25474246, PMCID: PMC4453614, DOI: 10.1038/bjc.2014.573.
• Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast CancerBrown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research 2014, 20: 5995-6005. PMID: 25255793, PMCID: PMC4252785, DOI: 10.1158/1078-0432.ccr-14-1622.
• Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic timeVassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, Kluger Y, Hicks DG, Rimm DL, Neumeister VM. Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. Laboratory Investigation 2014, 95: 334-341. PMID: 25418580, DOI: 10.1038/labinvest.2014.139.
• Quantitative Measurement of BIM Protein in Lung Cancer Diagnosis/StagingHenick B, Zarrella E, Altan M, McLaughlin J, Schalper K, Velcheti V, Rimm D. Quantitative Measurement of BIM Protein in Lung Cancer Diagnosis/Staging. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s11. DOI: 10.1016/j.ijrobp.2014.08.148.
• Abstract 933: Copy number changes are associated with BRAF and NRAS mutations and response to treatment with carboplatin, paclitaxel and sorafenibWilson M, Zhao F, Khare S, Letrero R, D'Andrea K, Rimm D, Kirkwood J, Kluger H, Lee S, Schuchter L, Flaherty K, Nathanson K. Abstract 933: Copy number changes are associated with BRAF and NRAS mutations and response to treatment with carboplatin, paclitaxel and sorafenib. 2014, 933-933. DOI: 10.1158/1538-7445.am2014-933.
• Abstract 2440: RNF5 mediates ER stress-induced degradation of SLC1A5 in breast cancerJeon Y, Khelifa S, Feng Y, Lau E, Cardiff R, Kim H, Rimm D, Kluger Y, Ronai Z. Abstract 2440: RNF5 mediates ER stress-induced degradation of SLC1A5 in breast cancer. 2014, 2440-2440. DOI: 10.1158/1538-7445.am2014-2440.
• Abstract 2840: Evaluation of HER-2 RNA and protein levels in a large cohort of breast cancer specimens to support development of a diagnostic immunofluorescence assay quantified by AQUA® TechnologyBordeaux J, Chandrasekaran K, Beruti S, Nerenberg M, Ramos C, Rimm D, Lameh J, Dakappagari N. Abstract 2840: Evaluation of HER-2 RNA and protein levels in a large cohort of breast cancer specimens to support development of a diagnostic immunofluorescence assay quantified by AQUA® Technology. 2014, 2840-2840. DOI: 10.1158/1538-7445.am2014-2840.
• Abstract 2843: Development of a binary diagnostic immunofluorescence assay by AQUA® technology for accurate detection of HER-2 levels in breast cancer specimensChandrasekaran L, Bordeaux J, Beruti S, Dakappagari N, Nerenberg M, Lameh J, Graber A, Rimm D, Robbins B, Rao N. Abstract 2843: Development of a binary diagnostic immunofluorescence assay by AQUA® technology for accurate detection of HER-2 levels in breast cancer specimens. 2014, 2843-2843. DOI: 10.1158/1538-7445.am2014-2843.
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals Of Oncology 2014, 26: 259-271. PMID: 25214542, PMCID: PMC6267863, DOI: 10.1093/annonc/mdu450.
• EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialCheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA. EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial. British Journal Of Cancer 2014, 111: 1065-1071. PMID: 25117817, PMCID: PMC4453859, DOI: 10.1038/bjc.2014.442.
• Unvalidated antibodies and misleading resultsRimm D, Schalper K, Pusztai L. Unvalidated antibodies and misleading results. Breast Cancer Research And Treatment 2014, 147: 457-458. PMID: 25086631, PMCID: PMC4216678, DOI: 10.1007/s10549-014-3061-0.
• Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling errorShipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British Journal Of Cancer 2014, 111: 1201-1212. PMID: 25032733, PMCID: PMC4453845, DOI: 10.1038/bjc.2014.396.
• Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethalityShipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P. Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality. Proteome Science 2014, 12: 40. PMID: 25075204, PMCID: PMC4114438, DOI: 10.1186/1477-5956-12-40.
• ERβ splice variant expression in four large cohorts of human breast cancer patient tumorsWimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL. ERβ splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Research And Treatment 2014, 146: 657-667. PMID: 25007965, PMCID: PMC6939385, DOI: 10.1007/s10549-014-3050-3.
• Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Annals Of Oncology 2014, 25: 2036-2041. PMID: 25009013, PMCID: PMC4176450, DOI: 10.1093/annonc/mdu248.
• Erratum: Next-gen immunohistochemistryRimm D. Erratum: Next-gen immunohistochemistry. Nature Methods 2014, 11: 773-773. DOI: 10.1038/nmeth0714-773c.
• In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer PatientsVassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A. In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. PLOS ONE 2014, 9: e99131. PMID: 24968015, PMCID: PMC4072595, DOI: 10.1371/journal.pone.0099131.
• Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and SorafenibWilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL. Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. Clinical Cancer Research 2014, 20: 3328-3337. PMID: 24714776, PMCID: PMC4058354, DOI: 10.1158/1078-0432.ccr-14-0093.
• Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. Clinical Cancer Research 2014, 20: 3023-3032. PMID: 24700741, PMCID: PMC4049169, DOI: 10.1158/1078-0432.ccr-14-0113.
• Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer.Brown J, Bai Y, Bossuyt V, Nixon C, Lannin D, Rimm D. Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2014, 32: 1027-1027. DOI: 10.1200/jco.2014.32.15_suppl.1027.
• Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC).McLaughlin J, Schalper K, Carvajal-Hausdorf D, Velcheti V, Haack H, Silver M, Goldberg S, Herbst R, Rimm D. Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2014, 32: 8064-8064. DOI: 10.1200/jco.2014.32.15_suppl.8064.
• Clinical significance of TILs subtypes in non-small cell lung cancer.Schalper K, Brown J, McLaughlin J, Herbst R, Rimm D. Clinical significance of TILs subtypes in non-small cell lung cancer. Journal Of Clinical Oncology 2014, 32: 8082-8082. DOI: 10.1200/jco.2014.32.15_suppl.8082.
• In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast CarcinomasSchalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas. Clinical Cancer Research 2014, 20: 2773-2782. PMID: 24647569, DOI: 10.1158/1078-0432.ccr-13-2702.
• Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumabCheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer 2014, 14: 326. PMID: 24885187, PMCID: PMC4037428, DOI: 10.1186/1471-2407-14-326.
• Automated Objective Determination of Percentage of Malignant Nuclei for Mutation TestingViray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, Schalper K, Hoyt C, Rimm DL. Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing. Applied Immunohistochemistry & Molecular Morphology 2014, 22: 363-371. PMID: 24162261, PMCID: PMC3999345, DOI: 10.1097/pai.0b013e318299a1f6.
• Su1894 Exome Sequencing of Formalin Fixed Paraffin Embedded Pancreatic Ductal Adenocarcinoma Samples Expands Mutational Landscape and Identifies Hypermutator PhenotypeVilarinho S, Overton J, Carvajal D, Rimm D, Lifton R. Su1894 Exome Sequencing of Formalin Fixed Paraffin Embedded Pancreatic Ductal Adenocarcinoma Samples Expands Mutational Landscape and Identifies Hypermutator Phenotype. Gastroenterology 2014, 146: s-495. DOI: 10.1016/s0016-5085(14)61783-2.
• Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC)Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC). PLOS ONE 2014, 9: e94273. PMID: 24722213, PMCID: PMC3983114, DOI: 10.1371/journal.pone.0094273.
• Next-gen immunohistochemistryRimm DL. Next-gen immunohistochemistry. Nature Methods 2014, 11: 381-383. PMID: 24681723, DOI: 10.1038/nmeth.2896.
• A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissueNeumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarrella E, Vassilakopolou M, Bai Y, Saylor S, Sapino A, Kluger Y, Hicks DG, Bussolati G, Kwei S, Rimm DL. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Laboratory Investigation 2014, 94: 467-474. PMID: 24535259, PMCID: PMC4030875, DOI: 10.1038/labinvest.2014.7.
• Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancerHow J, Brown JR, Saylor S, Rimm DL. Macrophage expression of tartrate-resistant acid phosphatase as a prognostic indicator in colon cancer. Histochemistry And Cell Biology 2014, 142: 195-204. PMID: 24429833, PMCID: PMC4101067, DOI: 10.1007/s00418-014-1181-6.
• In situ techniques for protein analysis in tumor tissueAnagnostou V, Rimm D. In situ techniques for protein analysis in tumor tissue. 2013, 76-84. DOI: 10.1017/cbo9781139046947.010.
• Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trialRimm D, Holmes E, Schalper K, Bradbury I, Zarrella E, Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez E. Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial. Cancer Research 2013, 73: p1-08-09-p1-08-09. DOI: 10.1158/0008-5472.sabcs13-p1-08-09.
• Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in breast cancerWimberly H, Schalper K, Chen L, Velcheti V, Pusztai L, Rimm D. Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in breast cancer. Cancer Research 2013, 73: p2-10-02-p2-10-02. DOI: 10.1158/0008-5472.sabcs13-p2-10-02.
• Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment MethodBai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF. Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method. PLOS ONE 2013, 8: e79901. PMID: 24278211, PMCID: PMC3836903, DOI: 10.1371/journal.pone.0079901.
• Programmed death ligand-1 expression in non-small cell lung cancerVelcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation 2013, 94: 107-116. PMID: 24217091, PMCID: PMC6125250, DOI: 10.1038/labinvest.2013.130.
• Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancerBrown JR, DiGiovanna MP, Killelea B, Lannin DR, Rimm DL. Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer. Laboratory Investigation 2013, 94: 98-106. PMID: 24189270, DOI: 10.1038/labinvest.2013.128.
• A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant CellsViray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, Halling KC, Hameed M, Rimm DL. A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant Cells. Archives Of Pathology & Laboratory Medicine 2013, 137: 1545-9. PMID: 24168492, DOI: 10.5858/arpa.2012-0561-cp.
• Construction and Analysis of Multiparameter Prognostic Models for Melanoma OutcomeRothberg BE, Rimm DL. Construction and Analysis of Multiparameter Prognostic Models for Melanoma Outcome. 2013, 1102: 227-258. PMID: 24258982, PMCID: PMC3912557, DOI: 10.1007/978-1-62703-727-3_13.
• A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists CriteriaSchalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A Retrospective Population-Based Comparison of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization in Breast Carcinomas: Impact of 2007 American Society of Clinical Oncology/ College of American Pathologists Criteria. Archives Of Pathology & Laboratory Medicine 2013, 138: 213-9. PMID: 24164555, DOI: 10.5858/arpa.2012-0617-oa.
• Gene Silencing in Skin After Deposition of Self-Delivery siRNA With a Motorized Microneedle Array DeviceHickerson RP, Wey WC, Rimm DL, Speaker T, Suh S, Flores MA, Gonzalez-Gonzalez E, Leake D, Contag CH, Kaspar RL. Gene Silencing in Skin After Deposition of Self-Delivery siRNA With a Motorized Microneedle Array Device. Molecular Therapy - Nucleic Acids 2013, 2: e129. PMID: 24150576, PMCID: PMC4027428, DOI: 10.1038/mtna.2013.56.
• TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancerMoretti E, Desmedt C, Biagioni C, Regan MM, Oakman C, Larsimont D, Galardi F, Piccart-Gebhart M, Sotiriou C, Rimm DL, Di Leo A. TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Future Oncology 2013, 9: 1477-1487. PMID: 24106899, DOI: 10.2217/fon.13.103.
• Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and PaclitaxelJilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM. Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLOS ONE 2013, 8: e69748. PMID: 23936348, PMCID: PMC3735539, DOI: 10.1371/journal.pone.0069748.
• Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous MelanomasViray H, Bradley WR, Schalper KA, Rimm DL, Rothberg B. Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas. Archives Of Pathology & Laboratory Medicine 2013, 137: 1063-73. PMID: 23899062, PMCID: PMC3963468, DOI: 10.5858/arpa.2012-0284-oa.
• Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR BiomarkerSgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. Journal Of The National Cancer Institute 2013, 105: 1036-1042. PMID: 23812955, PMCID: PMC3888138, DOI: 10.1093/jnci/djt146.
• Tissue microarrays: leaping the gap between research and clinical adoptionGustavson MD, Rimm DL, Dolled-Filhart M. Tissue microarrays: leaping the gap between research and clinical adoption. Personalized Medicine 2013, 10: 441-451. PMID: 29758838, DOI: 10.2217/pme.13.42.
• Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)Velcheti V, Rimm DL, Schalper KA. Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1). Journal Of Thoracic Oncology 2013, 8: 803-805. PMID: 23676558, PMCID: PMC3703468, DOI: 10.1097/jto.0b013e318292be18.
• Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA), paclitaxel (P), and cetuximab (C) induction and chemoradiation (CRT) in patients (pts) with resectable stage III/IVa,b head and neck squamous cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303.Psyrri A, Lee J, Vasilakopoulou M, Pectasides E, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA), paclitaxel (P), and cetuximab (C) induction and chemoradiation (CRT) in patients (pts) with resectable stage III/IVa,b head and neck squamous cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303. Journal Of Clinical Oncology 2013, 31: 6081-6081. DOI: 10.1200/jco.2013.31.15_suppl.6081.
• A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ.Hofstatter E, Stavris K, Horowitz N, Killelea B, Tsangaris T, Lannin D, Andrejeva L, Cong X, Yao X, Rimm D, Chagpar A. A pilot chemoprevention study of isopropanolic black cohosh extract in women with ductal carcinoma in situ. Journal Of Clinical Oncology 2013, 31: tps1609-tps1609. DOI: 10.1200/jco.2013.31.15_suppl.tps1609.
• Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC).Velcheti V, Schalper K, Carvajal D, Chen L, Sznol M, Gettinger S, Herbst R, Rimm D. Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2013, 31: 11075-11075. DOI: 10.1200/jco.2013.31.15_suppl.11075.
• Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer.Brown J, Lannin D, Killelea B, DiGiovanna M, Rimm D. Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2013, 31: 1085-1085. DOI: 10.1200/jco.2013.31.15_suppl.1085.
• Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma.Vasilakopoulou M, Velcheti V, Rampias T, Sasaki C, Rimm D, Fountzilas G, Psyrri A. Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2013, 31: 6012-6012. DOI: 10.1200/jco.2013.31.15_suppl.6012.
• High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian CancerLiu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, Alvero A, Silasi DA. High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer. Reproductive Sciences 2013, 20: 605-615. PMID: 23171677, PMCID: PMC3635069, DOI: 10.1177/1933719112461183.
• High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung CarcinomasVelcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, Deng Y, Gettinger S, Rimm DL. High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas. PLOS ONE 2013, 8: e61427. PMID: 23620753, PMCID: PMC3631238, DOI: 10.1371/journal.pone.0061427.
• Abstract 1569: Next generation cell line models: conditionally reprogrammed cells.Agarwal S, Hu J, Stanton K, Schalper K, Kluger Y, Zarrella E, Liu X, Schlegel R, Rimm D. Abstract 1569: Next generation cell line models: conditionally reprogrammed cells. Cancer Research 2013, 73: 1569-1569. DOI: 10.1158/1538-7445.am2013-1569.
• Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradationRajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping Lu K, Rimm DL, Alarid ET. Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. Oncogene 2013, 33: 1438-1447. PMID: 23542176, PMCID: PMC3815749, DOI: 10.1038/onc.2013.78.
• Quantitative Analysis of Estrogen Receptor Expression Shows SP1 Antibody Is More Sensitive Than 1D5Welsh AW, Harigopal M, Wimberly H, Prasad M, Rimm DL. Quantitative Analysis of Estrogen Receptor Expression Shows SP1 Antibody Is More Sensitive Than 1D5. Applied Immunohistochemistry & Molecular Morphology 2013, 21: 139-147. PMID: 22820659, PMCID: PMC3482297, DOI: 10.1097/pai.0b013e31825d73b2.
• Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotypeRampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A. Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype. Annals Of Oncology 2013, 24: 2124-2131. PMID: 23406730, DOI: 10.1093/annonc/mdt013.
• Abstract P3-14-01: Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).Colavito S, Stepansky A, Madan A, Harris L, Hicks J, Bossuyt V, Rimm D, Lannin D, Stern D. Abstract P3-14-01: Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). Cancer Research 2012, 72: p3-14-01-p3-14-01. DOI: 10.1158/0008-5472.sabcs12-p3-14-01.
• Abstract P3-06-25: PTEN mRNA positivity using in situ measurements is associated with better outcome in Tamoxifen treated breast cancer patients.Schalper K, Li K, Rimm D. Abstract P3-06-25: PTEN mRNA positivity using in situ measurements is associated with better outcome in Tamoxifen treated breast cancer patients. Cancer Research 2012, 72: p3-06-25-p3-06-25. DOI: 10.1158/0008-5472.sabcs12-p3-06-25.
• Abstract PD02-01: Her2 expression measured by AQUA analysis on BCIRG-005 and BCIRG-006 predicts the benefit of Herceptin therapyChristiansen J, Barakat N, Murphy D, Rimm D, Dabbas B, Nerenberg M, Beruti S, Quinaux E, Hall J, Press M, Slamon D. Abstract PD02-01: Her2 expression measured by AQUA analysis on BCIRG-005 and BCIRG-006 predicts the benefit of Herceptin therapy. Cancer Research 2012, 72: pd02-01-pd02-01. DOI: 10.1158/0008-5472.sabcs12-pd02-01.
• Abstract S5-4: EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial.Rimm D, Ballman K, Cheng H, Vassilakopoulou M, Chen B, Gralow J, Hudis C, Davidson N, Psyrri A, Fountzilas G, Perez E. Abstract S5-4: EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. Cancer Research 2012, 72: s5-4-s5-4. DOI: 10.1158/0008-5472.sabcs12-s5-4.
• Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer TissuesNeumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, Vassilakopoulou M, Parisi F, Kluger Y, Hicks DG, Rimm DL. Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues. Journal Of The National Cancer Institute 2012, 104: 1815-1824. PMID: 23090068, PMCID: PMC3514166, DOI: 10.1093/jnci/djs438.
• Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomesPeck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, Rui H. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Research 2012, 14: r130. PMID: 23036105, PMCID: PMC4053108, DOI: 10.1186/bcr3328.
• Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancerNeumeister VM, Sullivan CA, Lindner R, Lezon-Geyda K, Li J, Zavada J, Martel M, Glazer PM, Tuck DP, Rimm DL, Harris L. Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Research And Treatment 2012, 136: 67-75. PMID: 22976806, DOI: 10.1007/s10549-012-2232-0.
• Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancerAgarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Research 2012, 14: r124. PMID: 22971274, PMCID: PMC3962029, DOI: 10.1186/bcr3318.
• Gene expression array analysis to determine tissue of origin of carcinoma of unknown primaryDolled‐Filhart M, Rimm DL. Gene expression array analysis to determine tissue of origin of carcinoma of unknown primary. Cancer Cytopathology 2012, 121: 129-135. PMID: 22927160, DOI: 10.1002/cncy.21228.
• Delay to formalin fixation ‘cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistryPortier BP, Wang Z, Downs-Kelly E, Rowe JJ, Patil D, Lanigan C, Budd GT, Hicks DG, Rimm DL, Tubbs RR. Delay to formalin fixation ‘cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Modern Pathology 2012, 26: 1-9. PMID: 22899285, DOI: 10.1038/modpathol.2012.123.
• In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNAHanna JA, Hahn L, Agarwal S, Rimm DL. In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Laboratory Investigation 2012, 92: 1390-1397. PMID: 22890556, PMCID: PMC3460033, DOI: 10.1038/labinvest.2012.119.
• Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung CancerDimou A, Neumeister V, Agarwal S, Anagnostou V, Syrigos K, Rimm DL. Measurement of Aldehyde Dehydrogenase 1 Expression Defines a Group with Better Prognosis in Patients with Non-Small Cell Lung Cancer. American Journal Of Pathology 2012, 181: 1436-1442. PMID: 22877687, DOI: 10.1016/j.ajpath.2012.06.037.
• microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-β Signaling in GlioblastomaGenovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L. microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-β Signaling in Glioblastoma. Cancer Discovery 2012, 2: 736-749. PMID: 22750848, PMCID: PMC3911772, DOI: 10.1158/2159-8290.cd-12-0111.
• Spatial spectral imaging as an adjunct to the Bethesda classification of thyroid fine‐needle aspiration specimensHahn LD, Hoyt C, Rimm DL, Theoharis C. Spatial spectral imaging as an adjunct to the Bethesda classification of thyroid fine‐needle aspiration specimens. Cancer Cytopathology 2012, 121: 162-167. PMID: 22833451, DOI: 10.1002/cncy.21224.
• Lin28 regulates HER2 and promotes malignancy through multiple mechanismsFeng C, Neumeister V, Ma W, Xu J, Lu L, Bordeaux J, Maihle NJ, Rimm DL, Huang Y. Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle 2012, 11: 2486-2494. PMID: 22713243, DOI: 10.4161/cc.20893.
• Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC).Psyrri A, Lee J, Pectasides E, Vassilakopoulou M, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2012, 30: 5576-5576. DOI: 10.1200/jco.2012.30.15_suppl.5576.
• Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis.Velcheti V, Cheng H, Yao X, Deng Y, Gettinger S, Rimm D. Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis. Journal Of Clinical Oncology 2012, 30: e21106-e21106. DOI: 10.1200/jco.2012.30.15_suppl.e21106.
• Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?Chagpar A, Neumeister V, Lannin D, Rimm D. Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients? Journal Of Clinical Oncology 2012, 30: 1121-1121. DOI: 10.1200/jco.2012.30.15_suppl.1121.
• In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.Vassilakopoulou M, Bordeaux J, Neumeister V, Cheng H, Schalper K, Skarlos D, Pectasides D, Pavlidis N, Koutras A, Linardou H, Razis E, Bobos M, Kotoula V, Rimm D, Fountzilas G, Psyrri A. In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients. Journal Of Clinical Oncology 2012, 30: 573-573. DOI: 10.1200/jco.2012.30.15_suppl.573.
• Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.Christiansen J, Bartlett J, Gustavson M, Rimm D, Robson T, Van De Velde C, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D. Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. Journal Of Clinical Oncology 2012, 30: 517-517. DOI: 10.1200/jco.2012.30.15_suppl.517.
• Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to TamoxifenBordeaux JM, Cheng H, Welsh AW, Haffty BG, Lannin DR, Wu X, Su N, Ma XJ, Luo Y, Rimm DL. Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen. PLOS ONE 2012, 7: e36559. PMID: 22606272, PMCID: PMC3350519, DOI: 10.1371/journal.pone.0036559.
• Abstract 680: Loss of miR-34a as measured by quantitative in situ hybridization on a tissue microarray is associated with poor outcome in breast cancerAgarwal S, Hanna J, Rimm D. Abstract 680: Loss of miR-34a as measured by quantitative in situ hybridization on a tissue microarray is associated with poor outcome in breast cancer. Cancer Research 2012, 72: 680-680. DOI: 10.1158/1538-7445.am2012-680.
• Abstract 3626: Quantitative analysis of microRNAs by in situ hybridization reveals prognostic value of miRNAs in melanoma and breast cancerHanna J, Wimberly H, Kumar S, Agarwal S, Rimm D. Abstract 3626: Quantitative analysis of microRNAs by in situ hybridization reveals prognostic value of miRNAs in melanoma and breast cancer. Cancer Research 2012, 72: 3626-3626. DOI: 10.1158/1538-7445.am2012-3626.
• Abstract 689: Validation of antibodies to Estrogen Receptor ≤ and quantitative assessment of ERα1 and ERα5 expression in breast cancerWimberly H, Murphy L, Haffty B, Rimm D. Abstract 689: Validation of antibodies to Estrogen Receptor ≤ and quantitative assessment of ERα1 and ERα5 expression in breast cancer. Cancer Research 2012, 72: 689-689. DOI: 10.1158/1538-7445.am2012-689.
• Abstract 691: Estrogen receptor mRNA level in breast cancer predicts response to tamoxifenBordeaux J, Cheng H, Welsh A, Haffty B, Lannin D, Wu X, Su N, Ma X, Luo Y, Rimm D. Abstract 691: Estrogen receptor mRNA level in breast cancer predicts response to tamoxifen. Cancer Research 2012, 72: 691-691. DOI: 10.1158/1538-7445.am2012-691.
• Abstract 705: HER2 assessment to define outcomes for breast cancer patients treated with neoadjuvant therapyCheng H, Bai Y, Sikov W, Sinclair N, Abu-Khalaf M, Harris L, Rimm D. Abstract 705: HER2 assessment to define outcomes for breast cancer patients treated with neoadjuvant therapy. Cancer Research 2012, 72: 705-705. DOI: 10.1158/1538-7445.am2012-705.
• Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trialWilson M, Zhao F, Letrero R, D'Andrea K, Rimm D, Kirkwood J, Kluger H, Lee S, Flaherty K, Nathanson K. Abstract 5557: Mutation analysis of melanoma tumor samples from ECOG 2603 clinical trial. Cancer Research 2012, 72: 5557-5557. DOI: 10.1158/1538-7445.am2012-5557.
• Quantitative analysis of microRNAs in tissue microarrays by in situ hybridizationHanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. BioTechniques 2012, 52: 235-245. PMID: 22482439, PMCID: PMC3891915, DOI: 10.2144/000113837.
• Stathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancerBaquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL. Stathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer. Cancer 2012, 118: 4660-4669. PMID: 22359235, PMCID: PMC3391341, DOI: 10.1002/cncr.27453.
• Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer CellsZito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH. Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells. PLOS ONE 2012, 7: e31331. PMID: 22355357, PMCID: PMC3280285, DOI: 10.1371/journal.pone.0031331.
• PKCε Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function at MitochondriaLau E, Kluger H, Varsano T, Lee K, Scheffler I, Rimm DL, Ideker T, Ronai ZA. PKCε Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function at Mitochondria. Cell 2012, 148: 543-555. PMID: 22304920, PMCID: PMC3615433, DOI: 10.1016/j.cell.2012.01.016.
• Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancerAndre F, Conforti R, Moeder CB, Mauguen A, Arnedos M, Berrada N, Delaloge S, Tomasic G, Spielmann M, Esteva FJ, Rimm DL, Michiels S. Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Annals Of Oncology 2012, 23: 2059-2064. PMID: 22241898, DOI: 10.1093/annonc/mdr569.
• Cytoplasmic Estrogen Receptor in Breast CancerWelsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL. Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research 2012, 18: 118-126. PMID: 21980134, PMCID: PMC3263348, DOI: 10.1158/1078-0432.ccr-11-1236.
• Making Every Cell Like HeLa A Giant Step For Cell CultureAgarwal S, Rimm DL. Making Every Cell Like HeLa A Giant Step For Cell Culture. American Journal Of Pathology 2011, 180: 443-445. PMID: 22192626, DOI: 10.1016/j.ajpath.2011.12.001.
• P1-06-24: Nuclear Localization of Stat5a Predicts Response to Antiestrogen Therapy and Prognosis of Clinical Breast Cancer Outcome.Peck A, Witkiewicz A, Liu C, Klimowicz A, Stringer G, Pequignot E, Freydin B, Yang N, Tran T, Rosenberg A, Hooke J, Kovatich A, Shriver C, Rimm D, Magliocco A, Hyslop T, Rui H. P1-06-24: Nuclear Localization of Stat5a Predicts Response to Antiestrogen Therapy and Prognosis of Clinical Breast Cancer Outcome. Cancer Research 2011, 71: p1-06-24-p1-06-24. DOI: 10.1158/0008-5472.sabcs11-p1-06-24.
• P1-07-03: Preanalytical Variables Affect Protein Expression in Formalin Fixed Paraffin Embedded Tissue – Assessment of Intrinsic Controls To Define Tissue Quality for Immunohistochemical Analysis.Neumeister V, Lostritto K, Siddiqui S, Anagnostou V, Vassilakopoulou M, Zarrella E, Molinaro A, Hicks D, Rimm D. P1-07-03: Preanalytical Variables Affect Protein Expression in Formalin Fixed Paraffin Embedded Tissue – Assessment of Intrinsic Controls To Define Tissue Quality for Immunohistochemical Analysis. Cancer Research 2011, 71: p1-07-03-p1-07-03. DOI: 10.1158/0008-5472.sabcs11-p1-07-03.
• PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831.Perez E, Ballman K, Reinholz M, Dueck A, Cheng H, Jenkins R, McCullough A, Chen B, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Geiger X, Ingle J, Tenner K, Harris L, Gralow J, Rimm D. PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. Cancer Research 2011, 71: pd05-03-pd05-03. DOI: 10.1158/0008-5472.sabcs11-pd05-03.
• PD05-04: Quantitative Measurement of Antigen Degradation in NCCTG N9831 Tissue Microarrays.Cheng H, Rimm D, Reinholz M, Lingle W, Ballman K, Dueck A, Chen B, McCullough A, Jenkins R, Perez E. PD05-04: Quantitative Measurement of Antigen Degradation in NCCTG N9831 Tissue Microarrays. Cancer Research 2011, 71: pd05-04-pd05-04. DOI: 10.1158/0008-5472.sabcs11-pd05-04.
• Reply to A. ItalianoPeck A, Witkiewicz A, Liu C, Stringer G, Klimowicz A, Pequignot E, Freydin B, Tran T, Yang N, Rosenberg A, Hooke J, Kovatich A, Nevalainen M, Shriver C, Hyslop T, Sauter G, Rimm D, Magliocco A, Rui H. Reply to A. Italiano. Journal Of Clinical Oncology 2011, 29: 4718-4719. DOI: 10.1200/jco.2011.38.5187.
• β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient MelanomasDamsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Rothberg B, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M. β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. Cancer Cell 2011, 20: 741-754. PMID: 22172720, PMCID: PMC3241928, DOI: 10.1016/j.ccr.2011.10.030.
• C-Path: A Watson-Like Visit to the Pathology LabRimm DL. C-Path: A Watson-Like Visit to the Pathology Lab. Science Translational Medicine 2011, 3: 108fs8. PMID: 22072635, DOI: 10.1126/scitranslmed.3003252.
• Breast Cancer Misclassification: A Major Obstacle to Treatment?Romeo E, Gustavson MD, Rimm DL. Breast Cancer Misclassification: A Major Obstacle to Treatment? Women's Health 2011, 7: 615-618. PMID: 22040201, DOI: 10.2217/whe.11.69.
• A Pathway for the Control of Anoikis Sensitivity by E-Cadherin and Epithelial-to-Mesenchymal TransitionKumar S, Park SH, Cieply B, Schupp J, Killiam E, Zhang F, Rimm DL, Frisch SM. A Pathway for the Control of Anoikis Sensitivity by E-Cadherin and Epithelial-to-Mesenchymal Transition. Molecular And Cellular Biology 2011, 31: 4036-4051. PMID: 21746881, PMCID: PMC3187352, DOI: 10.1128/mcb.01342-10.
• Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohortsBaquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Research 2011, 13: r85. PMID: 21888627, PMCID: PMC3262195, DOI: 10.1186/bcr2937.
• Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assayAnagnostou VK, Dimou AT, Botsis T, Killiam EJ, Gustavson MD, Homer RJ, Boffa D, Zolota V, Dougenis D, Tanoue L, Gettinger SN, Detterbeck FC, Syrigos KN, Bepler G, Rimm DL. Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay. Cancer 2011, 118: 1607-1618. PMID: 22009766, DOI: 10.1002/cncr.26450.
• Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast CancerChagpar AB, Camp RL, Rimm DL. Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer. Annals Of Surgical Oncology 2011, 18: 3143. PMID: 21847696, DOI: 10.1245/s10434-011-2012-9.
• Quantification of Hormone Receptors to Guide Adjuvant Therapy Choice in Early Breast Cancer: Better Methods Required for Improved UtilityBartlett J, Rea D, Rimm DL. Quantification of Hormone Receptors to Guide Adjuvant Therapy Choice in Early Breast Cancer: Better Methods Required for Improved Utility. Journal Of Clinical Oncology 2011, 29: 3715-3716. PMID: 21810678, DOI: 10.1200/jco.2011.37.3704.
• Proinvasion Metastasis Drivers in Early-Stage Melanoma Are OncogenesScott K, Nogueira C, Heffernan T, van Doorn R, Dhakal S, Hanna J, Min C, Jaskelioff M, Xiao Y, Wu C, Cameron L, Perry S, Zeid R, Feinberg T, Kim M, Woude G, Granter S, Bosenberg M, Chu G, DePinho R, Rimm D, Chin L. Proinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes. Cancer Cell 2011, 20: 277. DOI: 10.1016/j.ccr.2011.08.005.
• Proinvasion Metastasis Drivers in Early-Stage Melanoma Are OncogenesScott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron LA, Perry SR, Zeid R, Feinberg T, Kim M, Woude G, Granter SR, Bosenberg M, Chu GC, DePinho RA, Rimm DL, Chin L. Proinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes. Cancer Cell 2011, 20: 92-103. PMID: 21741599, PMCID: PMC3176328, DOI: 10.1016/j.ccr.2011.05.025.
• Targeting Androgen Receptor in Estrogen Receptor-Negative Breast CancerNi M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M. Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer. Cancer Cell 2011, 20: 119-131. PMID: 21741601, PMCID: PMC3180861, DOI: 10.1016/j.ccr.2011.05.026.
• Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive CellsWelsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive Cells. Journal Of Clinical Oncology 2011, 29: 2978-2984. PMID: 21709197, PMCID: PMC3157961, DOI: 10.1200/jco.2010.32.9706.
• Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung CancerDimou A, Agarwal S, Anagnostou V, Viray H, Christensen S, Rothberg B, Zolota V, Syrigos K, Rimm DL. Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer. American Journal Of Pathology 2011, 179: 580-589. PMID: 21722621, PMCID: PMC3157192, DOI: 10.1016/j.ajpath.2011.04.031.
• p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC).Psyrri A, Ghebremichael M, Pectasides E, Dimou A, Burtness B, Rimm D, Wanebo H, Forastiere A. p16 protein status and response to treatment in a prospective clinical trial (ECOG 2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2011, 29: e16032-e16032. DOI: 10.1200/jco.2011.29.15_suppl.e16032.
• Optimal tumor sampling for immunostaining of biomarkers in breast carcinomaTolles J, Bai Y, Baquero M, Harris LN, Rimm DL, Molinaro AM. Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Research 2011, 13: r51. PMID: 21592345, PMCID: PMC3218938, DOI: 10.1186/bcr2882.
• Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy FailurePeck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H. Loss of Nuclear Localized and Tyrosine Phosphorylated Stat5 in Breast Cancer Predicts Poor Clinical Outcome and Increased Risk of Antiestrogen Therapy Failure. Journal Of Clinical Oncology 2011, 29: 2448-2458. PMID: 21576635, PMCID: PMC3675698, DOI: 10.1200/jco.2010.30.3552.
• Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell CarcinomaPectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2011, 17: 2947-2954. PMID: 21355076, DOI: 10.1158/1078-0432.ccr-10-2040.
• Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial TissuesRimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues. Journal Of Clinical Oncology 2011, 29: 2282-2290. PMID: 21519016, PMCID: PMC3107745, DOI: 10.1200/jco.2010.33.2023.
• Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variablesBai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Laboratory Investigation 2011, 91: 1253-1261. PMID: 21519325, PMCID: PMC3145004, DOI: 10.1038/labinvest.2011.75.
• Abstract 349: Fascin expression in colorectal cancer metastases predicts survival after curative-intent surgerySullivan C, Guo X, Wang Z, Theoharis C, Rimm D, Boffa D. Abstract 349: Fascin expression in colorectal cancer metastases predicts survival after curative-intent surgery. Cancer Research 2011, 71: 349-349. DOI: 10.1158/1538-7445.am2011-349.
• Abstract 2277: Loss of nuclear localized and tyrosine phosphorylated Stat5: A predictor of poor clinical outcome and increased risk of antiestrogen therapy failure in breast cancerPeck A, Witkiewicz A, Liu C, Stringer G, Klimowicz A, Pequignot E, Freydin B, Tran T, Yang N, Rosenberg A, Hooke J, Kovatich A, Nevalainen M, Shriver C, Hyslop T, Sauter G, Rimm D, Magliocco A, Rui H. Abstract 2277: Loss of nuclear localized and tyrosine phosphorylated Stat5: A predictor of poor clinical outcome and increased risk of antiestrogen therapy failure in breast cancer. Cancer Research 2011, 71: 2277-2277. DOI: 10.1158/1538-7445.am2011-2277.
• In vitro studies of dasatinib, its targets and predictors of sensitivityJilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell & Melanoma Research 2011, 24: 386-389. PMID: 21320292, PMCID: PMC4431976, DOI: 10.1111/j.1755-148x.2011.00835.x.
• Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II StudyOsborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study. Clinical Cancer Research 2011, 17: 1147-1159. PMID: 21220480, PMCID: PMC3074404, DOI: 10.1158/1078-0432.ccr-10-1869.
• Glucose and Inflammation Control Islet Vascular Density and β-Cell Function in NOD Mice Control of Islet Vasculature and Vascular Endothelial Growth Factor by GlucoseAkirav EM, Baquero MT, Opare-Addo LW, Akirav M, Galvan E, Kushner JA, Rimm DL, Herold KC. Glucose and Inflammation Control Islet Vascular Density and β-Cell Function in NOD Mice Control of Islet Vasculature and Vascular Endothelial Growth Factor by Glucose. Diabetes 2011, 60: 876-883. PMID: 21307078, PMCID: PMC3046848, DOI: 10.2337/db10-0793.
• Differential expression of arrestins is a predictor of breast cancer progression and survivalMichal AM, Peck AR, Tran TH, Liu C, Rimm DL, Rui H, Benovic JL. Differential expression of arrestins is a predictor of breast cancer progression and survival. Breast Cancer Research And Treatment 2011, 130: 791-807. PMID: 21318602, PMCID: PMC3156829, DOI: 10.1007/s10549-011-1374-9.
• Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistrySiddiqui S, Rimm DL. Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. Breast Cancer Research 2010, 12: 113. PMID: 21176180, PMCID: PMC3046444, DOI: 10.1186/bcr2782.
• Abstract PD10-09: Causes for False-Negative Estrogen Receptor (ER) Classification in Breast CancerWelsh A, Rimm D. Abstract PD10-09: Causes for False-Negative Estrogen Receptor (ER) Classification in Breast Cancer. Cancer Research 2010, 70: pd10-09-pd10-09. DOI: 10.1158/0008-5472.sabcs10-pd10-09.
• Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating MelanomaAziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM. Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma. Clinical Cancer Research 2010, 16: 6029-6039. PMID: 21169255, PMCID: PMC3058635, DOI: 10.1158/1078-0432.ccr-10-1490.
• Abstract P6-04-04: Hypoxia Is Associated with Somatic Loss of BRCA1 Protein and Pathway Activity in Triple Negative Breast CancerNeumeister V, Li J, Lindner R, Sullivan C, Glazer P, Tuck D, Rimm D, Harris L. Abstract P6-04-04: Hypoxia Is Associated with Somatic Loss of BRCA1 Protein and Pathway Activity in Triple Negative Breast Cancer. Cancer Research 2010, 70: p6-04-04-p6-04-04. DOI: 10.1158/0008-5472.sabcs10-p6-04-04.
• Abstract P3-10-16: Quantitative Subtractive Immunofluorescence To Develop a Surrogate for Mena Inv(asive) Isoform Is Associated with Poor Outcome in Breast CancerAgarwal S, Jones J, Oktay M, Balsamo M, Condeelis J, Gertler F, Rimm D. Abstract P3-10-16: Quantitative Subtractive Immunofluorescence To Develop a Surrogate for Mena Inv(asive) Isoform Is Associated with Poor Outcome in Breast Cancer. Cancer Research 2010, 70: p3-10-16-p3-10-16. DOI: 10.1158/0008-5472.sabcs10-p3-10-16.
• Abstract P3-10-26: Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 CohortSgroi D, Finkelstein D, Shepherd L, Ingle J, Rimm D, Sasano H, Porter P, Pins M, Paik S, Ristimaki A, Pritchard K, Tu D, Goss P. Abstract P3-10-26: Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort. Cancer Research 2010, 70: p3-10-26-p3-10-26. DOI: 10.1158/0008-5472.sabcs10-p3-10-26.
• Abstract P4-08-02: A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone ReceptorsBartlett J, Gustavson M, Stocken D, Rimm D, Christiansen J, van de Velde C, Hasenburg A, Kieback D, Putter H, Brookes C, Markopoulos C, Dirix L, Robson T, Seynaeve C, Dolled-Filhart M, Jones C, Graves L, McGuire J, Rea D. Abstract P4-08-02: A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors. Cancer Research 2010, 70: p4-08-02-p4-08-02. DOI: 10.1158/0008-5472.sabcs10-p4-08-02.
• Melanoma Tissue Microarray (TMA) Cohort and Data RepositoryRimm D. Melanoma Tissue Microarray (TMA) Cohort and Data Repository. Pigment Cell & Melanoma Research 2010, 23: 860-860. DOI: 10.1111/j.1755-148x.2010.00766.x.
• Subcellular Localization of NEDD9 AND HMB45 with AQUA Technology To Distinguish Spitz Nevi from MelanomaMcRae M, Lasova R, Narayan D, Rimm D. Subcellular Localization of NEDD9 AND HMB45 with AQUA Technology To Distinguish Spitz Nevi from Melanoma. Plastic & Reconstructive Surgery 2010, 126: 130-131. DOI: 10.1097/01.prs.0000388855.02380.53.
• Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor InhibitionGualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV. Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition. Clinical Cancer Research 2010, 16: 4654-4665. PMID: 20670944, PMCID: PMC2952544, DOI: 10.1158/1078-0432.ccr-10-0089.
• Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic modelsParisi F, González A, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research 2010, 12: r66. PMID: 20809974, PMCID: PMC3096952, DOI: 10.1186/bcr2633.
• Automated Analysis of Tissue MicroarraysDolled-Filhart M, Gustavson M, Camp RL, Rimm DL, Tonkinson JL, Christiansen J. Automated Analysis of Tissue Microarrays. 2010, 664: 151-162. PMID: 20690061, DOI: 10.1007/978-1-60761-806-5_15.
• Biomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous MelanomaRothberg B, Rimm DL. Biomarkers: The Useful and the Not So Useful—An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma. Journal Of Investigative Dermatology 2010, 130: 1971-1987. PMID: 20555347, PMCID: PMC3180927, DOI: 10.1038/jid.2010.149.
• The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epitheliumRokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE. The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Molecular Cancer 2010, 9: 150. PMID: 20550710, PMCID: PMC2894764, DOI: 10.1186/1476-4598-9-150.
• PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancerVanHouten J, Sullivan C, Bazinet C, Ryoo T, Camp R, Rimm DL, Chung G, Wysolmerski J. PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 11405-11410. PMID: 20534448, PMCID: PMC2895115, DOI: 10.1073/pnas.0911186107.
• What Are the Biggest Challenges and Opportunities for Biorepositories in the Next Three to Five Years?Betsou F, Rimm DL, Watson PH, Womack C, Hubel A, Coleman RA, Horn L, Terry SF, Zeps N, Clark BJ, Miranda LB, Hewitt RE, Elliott GD. What Are the Biggest Challenges and Opportunities for Biorepositories in the Next Three to Five Years? Biopreservation And Biobanking 2010, 8: 81-88. PMID: 24845936, DOI: 10.1089/bio.2010.8210.
• Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA.Pectasides E, Fountzilas G, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Rimm D, Burtness B, Psyrri D. Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA. Journal Of Clinical Oncology 2010, 28: 5538-5538. DOI: 10.1200/jco.2010.28.15_suppl.5538.
• The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss.Fountzilas G, Pectasides E, Kountourakis P, Gouveris P, Sasaki C, Duffey D, Pectasides D, Rimm D, Burtness B, Psyrri D. The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss. Journal Of Clinical Oncology 2010, 28: 5550-5550. DOI: 10.1200/jco.2010.28.15_suppl.5550.
• Molecular classification of non-small cell lung cancer using a four protein quantitative assay.Anagnostou V, Botsis T, Killiam E, Zolota V, Dougenis D, Tanoue L, Detterbeck F, Syrigos K, Bepler G, Rimm D. Molecular classification of non-small cell lung cancer using a four protein quantitative assay. Journal Of Clinical Oncology 2010, 28: 10528-10528. DOI: 10.1200/jco.2010.28.15_suppl.10528.
• Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by mutation-specific antibodies.Dimou A, Syrigos K, Agarwal S, Lozovatsky L, Zolota V, Anagnostou V, Rimm D. Frequency of L858R and D746-750 EGFR mutations in 411 Caucasian patients with non-small cell lung cancer measured by mutation-specific antibodies. Journal Of Clinical Oncology 2010, 28: 1587-1587. DOI: 10.1200/jco.2010.28.15_suppl.1587.
• High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histologyAnagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.
• Abstract 280: Met (the HGF receptor) localizes to the nucleus in wound healingBordeaux J, Hanna J, Agarwal S, Rimm D. Abstract 280: Met (the HGF receptor) localizes to the nucleus in wound healing. Cancer Research 2010, 70: 280-280. DOI: 10.1158/1538-7445.am10-280.
• Abstract 2234: Circulating tumor cells are rare in patients with curable oligometastatic cancerBoffa D, Guo X, Molinaro A, Finan B, Detterbeck F, Rimm D. Abstract 2234: Circulating tumor cells are rare in patients with curable oligometastatic cancer. Cancer Research 2010, 70: 2234-2234. DOI: 10.1158/1538-7445.am10-2234.
• Abstract 1753: High expression of the microtubule destabilizing protein stathmin is prognostic for worse outcome in breast cancerBaquero M, Hanna J, Agarwal S, Killiam E, Camp R, Rimm D. Abstract 1753: High expression of the microtubule destabilizing protein stathmin is prognostic for worse outcome in breast cancer. Cancer Research 2010, 70: 1753-1753. DOI: 10.1158/1538-7445.am10-1753.
• Abstract 4643: A novel 3-biomarker quantitative protein assay predicts survival in stage I lung squamous cell carcinomasAnagnostou V, Kolokytha P, Dimou A, Killiam E, Zolota V, Dougenis D, Frangia K, Tanoue L, Detterbeck F, Syrigos K, Bepler G, Rimm D. Abstract 4643: A novel 3-biomarker quantitative protein assay predicts survival in stage I lung squamous cell carcinomas. Cancer Research 2010, 70: 4643-4643. DOI: 10.1158/1538-7445.am10-4643.
• Abstract 1787: Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cellsChao H, Zito C, Jilaveanu L, Anagnostou V, Rimm D, Bepler G, Camp R, Kluger H. Abstract 1787: Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cells. Cancer Research 2010, 70: 1787-1787. DOI: 10.1158/1538-7445.am10-1787.
• Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better PrognosisPectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. Clinical Cancer Research 2010, 16: 2427-2434. PMID: 20371693, PMCID: PMC3030188, DOI: 10.1158/1078-0432.ccr-09-2658.
• Analytic Variability in Immunohistochemistry Biomarker StudiesAnagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL. Analytic Variability in Immunohistochemistry Biomarker Studies. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 982-991. PMID: 20332259, PMCID: PMC3891912, DOI: 10.1158/1055-9965.epi-10-0097.
• Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core?Anagnostou VK, Lowery FJ, Syrigos KN, Cagle PT, Rimm DL. Quantitative evaluation of protein expression as a function of tissue microarray core diameter: is a large (1.5 mm) core better than a small (0.6 mm) core? Archives Of Pathology & Laboratory Medicine 2010, 134: 613-9. PMID: 20367312, DOI: 10.5858/134.4.613.
• Quantitative Evaluation of Protein Expression as a Function of Tissue Microarray Core Diameter: Is a Large (1.5 mm) Core Better Than a Small (0.6 mm) Core?Anagnostou V, Lowery F, Syrigos K, Cagle P, Rimm D. Quantitative Evaluation of Protein Expression as a Function of Tissue Microarray Core Diameter: Is a Large (1.5 mm) Core Better Than a Small (0.6 mm) Core? Archives Of Pathology & Laboratory Medicine 2010, 134: 613-619. DOI: 10.5858/134.4.613.
• In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor PrognosisNeumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis. American Journal Of Pathology 2010, 176: 2131-2138. PMID: 20228222, PMCID: PMC2861079, DOI: 10.2353/ajpath.2010.090712.
• Antibody validationBordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, Rimm D. Antibody validation. BioTechniques 2010, 48: 197-209. PMID: 20359301, PMCID: PMC3891910, DOI: 10.2144/000113382.
• Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor OutcomeHarigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. American Journal Of Pathology 2010, 176: 1639-1647. PMID: 20150438, PMCID: PMC2843456, DOI: 10.2353/ajpath.2010.090711.
• Molecular Classification of Normal and Cancer Mammospheres.Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.
• Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study.Bartlett J, Rimm D, Brookes C, Dolled-Filhart M, Robson T, van de Velde C, Billingham L, Campbell F, Hasenburg A, Hille E, Kieback D, Putter H, Markopoulos C, Christiansen J, Gustavson M, Mallon E, Meershoek-Klein Kranenburg E, Parideans R, Seynaeve C, Rea D. Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study. Cancer Research 2009, 69: 3045-3045. DOI: 10.1158/0008-5472.sabcs-09-3045.
• A Quantitative Immunofluorescence Assay (AQUA) Suggests Significant Misclassification (15%) of Estrogen Receptor Status in Breast Cancer.Welsh A, Moeder C, Alarid E, Rimm D. A Quantitative Immunofluorescence Assay (AQUA) Suggests Significant Misclassification (15%) of Estrogen Receptor Status in Breast Cancer. Cancer Research 2009, 69: 4068-4068. DOI: 10.1158/0008-5472.sabcs-09-4068.
• Objective Spectral-Spatial Analysis of Random Periareolar Fine Needle Aspiration of Women at High Risk for Contralateral Breast Cancer.Zalles C, Zalles N, Mahooti S, Zahid F, Khan S, Rimm D. Objective Spectral-Spatial Analysis of Random Periareolar Fine Needle Aspiration of Women at High Risk for Contralateral Breast Cancer. Cancer Research 2009, 69: 6001-6001. DOI: 10.1158/0008-5472.sabcs-09-6001.
• Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysMehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Human Pathology 2009, 41: 375-384. PMID: 20004943, PMCID: PMC2824079, DOI: 10.1016/j.humpath.2009.08.016.
• Abstract ED01-04: Beyond IHC: Quantitative measurement of protein analytes on tissue slidesRimm D, Welsh A, Anagnostou V, Bai Y. Abstract ED01-04: Beyond IHC: Quantitative measurement of protein analytes on tissue slides. Molecular Cancer Therapeutics 2009, 8: ed01-04-ed01-04. DOI: 10.1158/1535-7163.targ-09-ed01-04.
• Abstract C21: Hypoxia-induced down-regulation of BRCA1 nuclear protein in human breast cancer tissuesLi J, Sullivan C, Numeister V, Rimm D, Glazer P, Harris L. Abstract C21: Hypoxia-induced down-regulation of BRCA1 nuclear protein in human breast cancer tissues. Molecular Cancer Therapeutics 2009, 8: c21-c21. DOI: 10.1158/1535-7163.targ-09-c21.
• Is ALDH1 a good method for definition of breast cancer stem cells?Neumeister V, Rimm D. Is ALDH1 a good method for definition of breast cancer stem cells? Breast Cancer Research And Treatment 2009, 123: 109-111. PMID: 19946740, DOI: 10.1007/s10549-009-0656-y.
• Melanoma Prognostic Model Using Tissue Microarrays and Genetic AlgorithmsRothberg B, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL. Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms. Journal Of Clinical Oncology 2009, 27: 5772-5780. PMID: 19884546, PMCID: PMC2792999, DOI: 10.1200/jco.2009.22.8239.
• DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic AssociationsGaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, Brinton LA, Rimm DL, Laird PW, Garcia-Closas M, Sherman ME. DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations. Cancer Epidemiology Biomarkers & Prevention 2009, 18: 3036-3043. PMID: 19861523, PMCID: PMC2783691, DOI: 10.1158/1055-9965.epi-09-0678.
• SP152 Beyond immunohistochemistry: Accurate, reproducible and quantitative measurement of protein analyte concentrations in fixed tissueRimm D. SP152 Beyond immunohistochemistry: Accurate, reproducible and quantitative measurement of protein analyte concentrations in fixed tissue. European Journal Of Cancer Supplements 2009, 7: 7. DOI: 10.1016/s1359-6349(09)72129-9.
• C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of MelanomasJilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas. Clinical Cancer Research 2009, 15: 5704-5713. PMID: 19737955, PMCID: PMC2763114, DOI: 10.1158/1078-0432.ccr-09-0198.
• Defining Molecular Phenotypes of Human Papillomavirus–Associated Oropharyngeal Squamous Cell CarcinomaWeinberger PM, Yu Z, Kountourakis P, Sasaki C, Haffty BG, Kowalski D, Merkley MA, Rimm DL, Camp RL, Psyrri A. Defining Molecular Phenotypes of Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma. Otolaryngology 2009, 141: 382-389. PMID: 19716018, DOI: 10.1016/j.otohns.2009.04.014.
• 1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transitionGualberto A, Hixon M, Dolled-Filhart M, Chistensen J, Rimm D, Lee A, Wang Y, Pollak M, Paz-Ares L, Karp D. 1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition. European Journal Of Cancer Supplements 2009, 7: 88-89. DOI: 10.1016/s1359-6349(09)70299-x.
• Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancerNadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Annals Of Oncology 2009, 21: 466-473. PMID: 19717535, PMCID: PMC2826097, DOI: 10.1093/annonc/mdp346.
• Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresCreighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106: 13820-13825. PMID: 19666588, PMCID: PMC2720409, DOI: 10.1073/pnas.0905718106.
• High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung AdenocarcinomaAnagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.
• GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancerScott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L. GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009, 459: 1085-1090. PMID: 19553991, PMCID: PMC2753613, DOI: 10.1038/nature08109.
• Association of expression of bcl-2 with outcome in non-small cell lung cancerAnagnostou V, Lowery F, Syrigos K, Frangia K, Zolota V, Panagopoulos N, Dougenis D, Tanoue L, Detterbeck F, Homer R, Rimm D. Association of expression of bcl-2 with outcome in non-small cell lung cancer. Journal Of Clinical Oncology 2009, 27: e22039-e22039. DOI: 10.1200/jco.2009.27.15_suppl.e22039.
• Construction of a five-marker protein-based model for stage-independent assessment of prognosis in breast cancerGiltnane J, Rapp J, Moeder C, Camp R, Kluger H, Molinaro A, Rimm D. Construction of a five-marker protein-based model for stage-independent assessment of prognosis in breast cancer. Journal Of Clinical Oncology 2009, 27: 11013-11013. DOI: 10.1200/jco.2009.27.15_suppl.11013.
• Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technologyGustavson M, Welsh A, Jones C, Mayotte J, Tu J, Hopkins J, Rimm D, Christiansen J. Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology. Journal Of Clinical Oncology 2009, 27: 567-567. DOI: 10.1200/jco.2009.27.15_suppl.567.
• Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLCGualberto A, Dolled-Filhart M, Hixon M, Christensen J, Rimm D, Lee A, Wang Y, Pollak M, Paz-Ares L, Karp D. Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. Journal Of Clinical Oncology 2009, 27: 8091-8091. DOI: 10.1200/jco.2009.27.15_suppl.8091.
• Phosphatidylinositol-3-Kinase as a Therapeutic Target in MelanomaAziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. Clinical Cancer Research 2009, 15: 3029-3036. PMID: 19383818, PMCID: PMC4431617, DOI: 10.1158/1078-0432.ccr-08-2768.
• The Semaphorin 7A Receptor Plexin C1 Is Lost During Melanoma MetastasisLazova R, Rothberg B, Rimm D, Scott G. The Semaphorin 7A Receptor Plexin C1 Is Lost During Melanoma Metastasis. American Journal Of Dermatopathology 2009, 31: 177-181. PMID: 19318806, DOI: 10.1097/dad.0b013e318196672d.
• Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysisRothberg B, Bracken MB, Rimm DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. Journal Of The National Cancer Institute 2009, 101: 452-474. PMID: 19318635, PMCID: PMC2720709, DOI: 10.1093/jnci/djp038.
• Gab2-Mediated Signaling Promotes Melanoma MetastasisHorst B, Gruvberger-Saal SK, Hopkins BD, Bordone L, Yang Y, Chernoff KA, Uzoma I, Schwipper V, Liebau J, Nowak NJ, Brunner G, Owens D, Rimm DL, Parsons R, Celebi JT. Gab2-Mediated Signaling Promotes Melanoma Metastasis. American Journal Of Pathology 2009, 174: 1524-1533. PMID: 19342374, PMCID: PMC2671382, DOI: 10.2353/ajpath.2009.080543.
• Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohortGiltnane JM, Moeder CB, Camp RL, Rimm DL. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009, 115: 2400-2409. PMID: 19330842, PMCID: PMC2756449, DOI: 10.1002/cncr.24277.
• Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cellsAgarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, DiGiovanna MP, Stern DF. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. British Journal Of Cancer 2009, 100: 941-949. PMID: 19240716, PMCID: PMC2661782, DOI: 10.1038/sj.bjc.6604937.
• Quantitative, Fluorescence-Based In-Situ Assessment of Protein ExpressionMoeder CB, Giltnane JM, Moulis SP, Rimm DL. Quantitative, Fluorescence-Based In-Situ Assessment of Protein Expression. 2009, 520: 163-175. PMID: 19381954, DOI: 10.1007/978-1-60327-811-9_12.
• Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and SorafenibJilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research 2009, 15: 1076-1085. PMID: 19188183, PMCID: PMC4263281, DOI: 10.1158/1078-0432.ccr-08-2280.
• Activated Wnt/ß-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma modelChien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm DL, Moon RT. Activated Wnt/ß-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proceedings Of The National Academy Of Sciences Of The United States Of America 2009, 106: 1193-1198. PMID: 19144919, PMCID: PMC2626610, DOI: 10.1073/pnas.0811902106.
• Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney CancerLiu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T, Rzhetsky A, White KP. Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney Cancer. Science 2009, 323: 1218-1222. PMID: 19164706, PMCID: PMC2756524, DOI: 10.1126/science.1157669.
• Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840.Rimm D, Broadwater G, Friedman P, Berry D, Seidman A, Hudis C, Winer E, Harris L, Thor A. Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. Cancer Research 2009, 69: 6046. DOI: 10.1158/0008-5472.sabcs-6046.
• In situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays.Neumeister V, Agarwal S, Camp R, Rimm D. In situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays. Cancer Research 2009, 69: 102. DOI: 10.1158/0008-5472.sabcs-102.
• Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment.Rimm D, Barlow W, Harigopal M, Tedeschi G, Peggy P, Yeh I, Haskell C, Livingston R, Hortobagyi G, Hayes D. Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment. Cancer Research 2009, 69: 704. DOI: 10.1158/0008-5472.sabcs-704.
• Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer.Conforti R, Moeder C, Tomasic G, Boulet T, Nahta R, Yuan L, Spielmann M, Delaloge S, Michiels S, Rimm D, Esteva F, Andre F. Predictive value of p27 for the benefit of adjuvant anthracycline-based chemotherapy in early breast cancer. Cancer Research 2009, 69: 6063. DOI: 10.1158/0008-5472.sabcs-6063.
• Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in CancerHanna JA, Bordeaux J, Rimm DL, Agarwal S. Chapter 1 The Function, Proteolytic Processing, and Histopathology of Met in Cancer. 2009, 103: 1-23. PMID: 19854350, DOI: 10.1016/s0065-230x(09)03001-2.
• Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple ImputationEmerson JW, Dolled-Filhart M, Harris L, Rimm DL, Tuck DP. Quantitative Assessment of Tissue Biomarkers and Construction of a Model to Predict Outcome in Breast Cancer Using Multiple Imputation. Cancer Informatics 2008, 7: cin.s911. PMID: 19352457, PMCID: PMC2664700, DOI: 10.4137/cin.s911.
• Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung AdenocarcinomaAnagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid Transcription Factor 1 Is an Independent Prognostic Factor for Patients With Stage I Lung Adenocarcinoma. Journal Of Clinical Oncology 2008, 27: 271-278. PMID: 19064983, DOI: 10.1200/jco.2008.17.0043.
• Aqua® Technology and Molecular PathologyGustavson M, Dolled‐Filhart M, Christiansen J, Pinard R, Rimm D. Aqua® Technology and Molecular Pathology. 2008, 295-333. DOI: 10.1002/9780470475959.ch11.
• AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma.Gustavson MD, Molinaro AM, Tedeschi G, Camp RL, Rimm DL. AQUA analysis of thymidylate synthase reveals localization to be a key prognostic biomarker in 2 large cohorts of colorectal carcinoma. Archives Of Pathology & Laboratory Medicine 2008, 132: 1746-52. PMID: 18976010, DOI: 10.5858/132.11.1746.
• AQUA Analysis of Thymidylate Synthase Reveals Localization to be a Key Prognostic Biomarker in 2 Large Cohorts of Colorectal CarcinomaGustavson M, Molinaro A, Tedeschi G, Camp R, Rimm D. AQUA Analysis of Thymidylate Synthase Reveals Localization to be a Key Prognostic Biomarker in 2 Large Cohorts of Colorectal Carcinoma. Archives Of Pathology & Laboratory Medicine 2008, 132: 1746-1752. DOI: 10.5858/132.11.1746.
• A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer BiomarkersCamp RL, Neumeister V, Rimm DL. A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers. Journal Of Clinical Oncology 2008, 26: 5630-5637. PMID: 18936473, DOI: 10.1200/jco.2008.17.3567.